CTI BioPharma (CTIC) 10-K 13 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Mar. 06, 2020	Jun. 30, 2019
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Registrant Name	CTI BIOPHARMA CORP.
Entity Central Index Key	0000891293
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		73,678,720
Entity Public Float			$ 43.7

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 31,144	$ 36,439
Short-term investments	2,522	30,599
Receivables from license and development services arrangements	0	13,679
Prepaid expenses and other current assets	1,914	1,775
Total current assets	35,580	82,492
Property and equipment, net	1,235	1,793
Other assets	9,465	5,547
Total assets	46,280	89,832
Current liabilities:
Accounts payable	0	4,498
Accrued expenses	11,606	12,852
Current portion of long-term debt	4,812	4,812
Other current liabilities	2,070	893
Total current liabilities	18,488	23,055
Long-term debt, less current portion	4,455	9,267
Other liabilities	5,407	4,571
Total liabilities	28,350	36,893
Commitments and contingencies (Note 18)
Stockholders' equity:
Common stock, $0.001 par value per share: Authorized shares - 131,500,000 and 101,500,000 as of December 31, 2019 and 2018, respectively, Issued and outstanding shares - 57,979,725 and 57,986,075 as of December 31, 2019 and 2018, respectively	58	58
Additional paid-in capital	2,299,186	2,294,025
Accumulated other comprehensive loss	(11,993)	(10,643)
Accumulated deficit	(2,263,563)	(2,224,746)
Total CTI stockholders' equity	23,688	58,694
Noncontrolling interest	(5,758)	(5,755)
Total stockholders' equity	17,930	52,939
Total liabilities and stockholders' equity	46,280	89,832
Preferred stock, $0.001 par value per share: Authorized shares - 33,333, Series O Preferred Stock, 12,575 shares issued and outstanding as of December 31, 2019 and 2018 (Aggregate liquidation preference of $25,150 as of December 31, 2019 and 2018, respectively)
Stockholders' equity:
Preferred stock, Series O and N, $0.001 par value per share	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Common stock par value (in USD per share)	$ 0.001	$ 0.001
Common stock authorized (in shares)	131,500,000	101,500,000
Common stock issued (in shares)	57,979,725	57,986,075
Common stock outstanding (in shares)	57,979,725	57,986,075
Series O convertible preferred stock
Preferred stock par value (in USD per share)	$ 0.001	$ 0.001
Preferred stock authorized (in shares)	33,333	33,333
Preferred stock issued (in shares)	12,575	12,575
Preferred stock outstanding (in shares)	12,575	12,575
Preferred stock liquidation preference	$ 25,150	$ 25,150

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
License and contract revenues	$ 3,345	$ 26,290
Operating costs and expenses:
Research and development	24,107	36,467
Selling, general and administrative	19,155	22,062
Restructuring expenses	794	660
Total operating costs and expenses	44,056	59,189
Loss from operations	(40,711)	(32,899)
Non-operating income (expense):
Interest income	1,172	1,219
Interest expense	(1,002)	(1,209)
Amortization of debt discount and issuance costs	(521)	(525)
Foreign exchange loss	(281)	(233)
Other non-operating income	1,320	4,295
Total non-operating income, net	688	3,547
Net loss before noncontrolling interest	(40,023)	(29,352)
Noncontrolling interest	3	32
Net loss	(40,020)	(29,320)
Deemed dividends on preferred stock	0	(80)
Net loss attributable to common stockholders	$ (40,020)	$ (29,400)
Basic and diluted net loss per common share (in USD per share)	$ (0.69)	$ (0.52)
Shares used in calculation of basic and diluted net loss per common share (in shares)	57,974	56,073

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Net loss before noncontrolling interest	$ (40,023)	$ (29,352)
Other comprehensive (loss) income:
Foreign currency translation adjustments	(2,323)	(2,843)
Unrealized foreign exchange gain (loss) on intercompany balance	957	(1,513)
Net unrealized gain (loss) on securities available-for-sale	16	(15)
Other comprehensive loss	(1,350)	(4,371)
Comprehensive loss	(41,373)	(33,723)
Comprehensive loss attributable to noncontrolling interest	3	32
Comprehensive loss attributable to CTI	$ (41,370)	$ (33,691)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interest
Beginning Balance (in shares) at Dec. 31, 2017		1	42,969
Beginning Balance at Dec. 31, 2017	$ 16,090	$ 0	$ 43	$ 2,223,388	$ (6,272)	$ (2,195,346)	$ (5,723)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs (in shares)			23,000
Issuance of common stock, net of issuance costs	64,170		$ 23	64,147
Exchange of common stock for preferred stock (in shares)		12	(8,000)
Exchange of common stock for preferred stock	0		$ (8)	8
Value of beneficial conversion features related to preferred stock	0			80		(80)
Equity-based compensation	6,369			6,369
Noncontrolling interest	(32)						(32)
Other (in shares)			17
Other	33			33
Net loss for the year	(29,320)					(29,320)
Other comprehensive loss	(4,371)				(4,371)
Ending Balance (in shares) at Dec. 31, 2018		13	57,986
Ending Balance at Dec. 31, 2018	52,939	$ 0	$ 58	2,294,025	(10,643)	(2,224,746)	(5,755)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation	5,166			5,166
Noncontrolling interest	(3)						(3)
Other (in shares)			(6)
Other	2			2
Net loss for the year	(40,020)					(40,020)
Other comprehensive loss	(1,350)				(1,350)
Ending Balance (in shares) at Dec. 31, 2019		13	57,980
Ending Balance at Dec. 31, 2019	$ 17,930	$ 0	$ 58	$ 2,299,186	$ (11,993)	$ (2,263,563)	$ (5,758)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating activities
Net loss before noncontrolling interest	$ (40,023)	$ (29,352)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	5,166	6,369
Depreciation and amortization	546	593
Gain on dissolution of foreign entities	(1,332)	(4,288)
Noncash interest expense	521	525
Noncash rent benefit	(653)	(1,424)
Other	191	794
Changes in operating assets and liabilities:
Receivables from license and development services arrangements	13,674	(12,389)
Prepaid expenses and other assets	1,120	(163)
Accounts payable and accrued expenses	(5,463)	923
Deferred revenue and other	(1,569)	(1,412)
Net cash used in operating activities	(27,822)	(39,824)
Investing activities
Purchases of property and equipment	0	(33)
Purchases of short-term investments	(11,018)	(42,067)
Proceeds from maturities of short-term investments	39,150	11,610
Net cash provided by (used in) investing activities	28,132	(30,490)
Financing activities
Proceeds from common stock offering, net of issuance costs	0	64,170
Cash paid for offering costs	(275)	(268)
Repayment of debt	(5,333)	(444)
Payment of tax withholding obligations related to restricted stock awards	0	(21)
Proceeds from stock option exercises and ESPP stock issuance	1	54
Net cash (used in) provided by financing activities	(5,607)	63,491
Effect of exchange rate changes on cash and cash equivalents	2	44
Net decrease in cash and cash equivalents	(5,295)	(6,779)
Cash and cash equivalents at beginning of year	36,439	43,218
Cash and cash equivalents at end of year	31,144	36,439
Supplemental disclosure of cash flow information
Cash paid during the period for interest	1,044	1,197
Supplemental disclosure of noncash financing and investing activities
Exchange of common stock and preferred stock for preferred stock	$ 0	$ 24,080

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Description of Business and Summary of Significant Accounting Policies	1. Description of Business and Summary of Significant Accounting Policies CTI BioPharma Corp., together with its wholly-owned subsidiary, also referred to collectively in this Annual Report on Form 10-K as “we,” “us,” “our,” the “Company” and “CTI,” is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products requires approval from, and is subject to, ongoing oversight by the Food and Drug Administration, or the FDA, in the United States, the European Medicines Agency, or the EMA, in the European Union, or the EU, and comparable agencies in other countries. Obtaining approval for a new therapeutic product is never certain, may take many years and may involve expenditure of substantial resources. Principles of Consolidation The accompanying consolidated financial statements include the accounts of CTI and its wholly-owned subsidiary, CTI Life Sciences Limited, or CTILS, until its dissolution in November 2019. As of December 31, 2019 , we also had an approximately 60% interest in our majority-owned subsidiary, Aequus Biopharma, Inc., or Aequus. The remaining interest in Aequus not held by CTI is reported as noncontrolling interest in the consolidated financial statements. All intercompany transactions and balances are eliminated in consolidation. Reincorporation Merger In January 2018, we effected a reincorporation merger, or the Reincorporation, following approval by our Board and our shareholders at our Special Meeting of Shareholders held on January 24, 2018, for the sole purpose of changing the state of incorporation from the State of Washington to the State of Delaware. Prior to the Reincorporation, our preferred stock and common stock had no par value. Subsequent to the Reincorporation, our preferred stock and common stock each have a par value of $0.001 per share. There was no impact on our assets and liabilities as a result of the Reincorporation. Liquidity The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. Our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. In March 2020, as discussed in Note 18. Subsequent Events , we completed the closing of our rights offering and received approximately $59.3 million in net proceeds. Based on our evaluation completed pursuant to Accounting Standards Update No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, we expect that, as of the date of the filing of this Annual Report on Form 10-K, our present financial resources, together with the net proceeds we received from our rights offering, will be sufficient to meet our obligations as they come due and to fund our operations into the first quarter of 2022. Accordingly, the conditions that previously raised substantial doubt about our ability to continue as a going concern as of the date of the filing of our Quarterly Report on Form 10-Q as of and for the three and nine months ended September 30, 2019, have been alleviated. We will need to continue to conduct research, development, testing and regulatory compliance activities with respect to our compounds and ensure the procurement of manufacturing and drug supply services, the costs of which, together with projected general and administrative expenses, is expected to result in operating losses for the foreseeable future. In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of a Development, Commercialization and License Agreement, or the Pacritinib License Agreement, with Baxalta and are no longer eligible to receive cost sharing or milestone payments for pacritinib's development. We have incurred a net operating loss every year since our formation. As of December 31, 2019 , we had an accumulated deficit of $2.3 billion , and we expect to incur net losses for the foreseeable future. Our available cash, cash equivalents and short-term investments were $33.7 million as of December 31, 2019 . We will need to acquire additional funds in order to develop our business and continue the development of pacritinib. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding obtained through the sale of such shares or otherwise may not be sufficient, available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing stockholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly-qualified personnel, be unable to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. The amount of financing we require is dependent on many factors, such as the number of clinical trial sites, the number of patients in the trial, the pace of patient enrollment and other matters that may impact clinical development, including changes to the trial that we may initiate or that may be requested by the FDA or other regulators, and there can be no assurance as to the amount of funding necessary to fund the development of pacritinib to completion. In addition, our ability to comply with covenants under the loan and security agreement with Silicon Valley Bank, or SVB, may be affected by events beyond our control, and we may not be able to meet those covenants. A breach of any of these covenants, including a material adverse change in our business, operations or condition (financial or otherwise) could result in an event of default under the loan and security agreement, which could cause all of the outstanding indebtedness under the facility to become immediately due and payable. The accompanying consolidated financial statements do not include adjustments, if any, that may result from the outcome of this uncertainty. Use of Estimates The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. For example, estimates include assumptions used in calculating share-based compensation expense, accruals, the allocation of operating expenses, provision for loss contingencies, the fair value of financial instruments, our tax provision and related valuation allowance, determining the useful lives of fixed assets and potential impairment of long-lived assets. Actual results could differ from those estimates. Certain Risks, Uncertainties and Concentrations We are exposed to risks associated with the translation of euro-denominated financial results and accounts into U.S. dollars for financial reporting purposes. The carrying values of the assets and liabilities, as well as the reported amounts of revenues and expenses are affected by fluctuations in the value of the U.S. dollar as compared to the euro. Certain of our transactions denote monetary amounts in foreign currencies, and consequently, the ultimate financial impact to us from a U.S. dollar perspective is subject to significant uncertainty. We review our foreign currency risk periodically along with hedging options to mitigate such risk. We source our drug products for clinical trials from a concentrated group of third-party contractors. If we are unable to obtain sufficient quantities of source materials, manufacture or distribute our products to customers from existing suppliers and service providers, or obtain the materials or services from other suppliers, manufacturers or distributors, certain research and development and sales activities may be delayed. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: • Level 1—Valuations based on unadjusted quoted prices for identical assets and liabilities in active markets. • Level 2—Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Valuations based on unobservable inputs that are supported by little or no market activity, reflecting our own assumptions. These valuations require significant judgment or estimation. Our cash equivalents and short-term investments are recorded at fair value. As of December 31, 2019 and 2018 , our cash, cash equivalents and short-term investments consisted of cash, money market funds, U.S. government and agency securities and corporate debt securities. We measure the fair value of money market funds based on the closing price reported by a fund sponsor from an actively traded exchange. We value all other securities using broker quotes that utilize observable market inputs. We did not hold cash, cash equivalents and short-term investments categorized as Level 3 assets as of December 31, 2019 and 2018 . The following table summarizes, by major security type, our cash, cash equivalents and short-term investments that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands): December 31, 2019 December 31, 2018 Cost or Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Total Estimated Fair Value Total Estimated Fair Value Cash $ 188 $ — $ — $ 188 $ 919 Level 1 securities: Money market funds 28,957 — — 28,957 20,525 Level 2 securities: U.S. government and agency securities 2,522 — — 2,522 15,213 Corporate debt securities 1,999 — — 1,999 30,381 Total cash, cash equivalents and short-term investments $ 33,666 $ — $ — $ 33,666 $ 67,038 There were no other financial instruments requiring fair value measurement as of December 31, 2019 and 2018 . At December 31, 2019 and 2018 , the carrying value of our receivables and payables approximated their fair values due to their short-term maturities. The carrying value of our long-term debt approximated its fair value at December 31, 2019 and 2018 based on borrowing rates for similar loans and maturities. Cash and Cash Equivalents We consider all highly liquid instruments with original maturities of three months or less at the time acquired to be cash equivalents. Receivables from License and Development Services Arrangements Our receivables relate to amounts payable or reimbursable to us under the terms of license and development services arrangements with our partners. The receivable balance as of December 31, 2018 related primarily to a milestone receivable from Servier for the attainment of a regulatory milestone in November 2018 as well as a milestone receivable from Teva for the attainment of a worldwide net sales milestone of TRISENOX in December 2018. There were no such receivables as of December 31, 2019 . Receivables are reviewed for collectability whenever circumstances indicate that the carrying amount of the receivable may not be recoverable. We had no allowance for doubtful accounts from license and development services arrangements as of December 31, 2019 and 2018 . Italian Value Added Tax Receivable We historically carried out research and development activities in Italy and incurred value added tax, or VAT, from Italian suppliers on the acquisition of goods and services in Italy. This VAT should be considered as an Input VAT credit. We treated the majority of our sales made in Italy without output VAT (on the basis that the supplies should be considered outside the scope of Italian VAT). This resulted in the value of input VAT exceeding the value of output VAT, and accordingly we submitted a refund claim for the VAT. The Italian Tax Authority, or the ITA, has challenged the treatment of the sales transactions and claimed that the sales transactions made by us should have been subject to output VAT. Our Italian VAT receivable was approximately $4.4 million and $4.5 million as of December 31, 2019 and 2018 , respectively. Substantially all of our VAT receivable is included in Other assets . As disclosed in Note 16. Commitments and Contingencies , the ITA assessed us for additional VAT payments for services we provided in Italy, which we do not believe we owe. We have not recorded an amount in the financial statements for this contingent liability as we do not believe the potential payment of up to €4.3 million (or approximately $4.8 million converted using the currency exchange rate as of December 31, 2019 ), to the ITA is probable at this time. Leases As discussed in Recently Adopted Accounting Standards below, we adopted Accounting Standards Codification, or ASC, Topic 842 - Leases, on January 1, 2019. Under ASC 842, we determine if an arrangement is a lease at inception. We recognize a right-of-use asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as operating or finance at lease commencement, which will affect the pattern and classification of expense recognition in our consolidated statements of operations. Right-of-use assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our leases do not provide a readily determinable implicit rate of return, we use our incremental borrowing rate to derive the present value of lease payments, which is the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. An operating lease right-of-use asset is measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentives received, unamortized initial direct costs and the impairment of the right-of-use asset. A lease may include options to extend or terminate the lease. When it is reasonably certain that we will exercise such an option, it is considered in the lease term. Right-of-use assets are tested for impairment in the same manner as long-lived assets used in operations. Leasehold improvements are capitalized at cost and amortized over the lesser of their expected useful life or the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term as part of Research and development expenses and Selling, general and administrative expenses in our consolidated statements of operations. Right-of-use assets are included in Other assets. The current portion of lease liabilities and the non-current portion of lease liabilities are included in Other current liabilities and Other liabilities , respectively, in our consolidated balance sheets. Property and Equipment Property and equipment are carried at cost, less accumulated depreciation and amortization. Depreciation commences at the time assets are placed in service. We calculate depreciation using the straight-line method over the estimated useful lives of the assets, ranging from three to five years for assets other than leasehold improvements. We amortize leasehold improvements over the lesser of their useful lives of 10 years or the term of the applicable lease. Impairment of Long-lived Assets We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If an impairment is indicated, the asset is written down to its estimated fair value. Contingencies We record liabilities associated with loss contingencies to the extent that we conclude that the occurrence of the contingency is probable and that the amount of the related loss is reasonably estimable. We record income from gain contingencies only upon the realization of assets resulting from the favorable outcome of the contingent event. See Note 10. Collaboration, Licensing and Milestone Agreements and Note 16. Commitments and Contingencies for further information regarding our current contingencies. Revenue Recognition ASC 606 - Revenue from Contracts with Customers applies to all contracts with customers, except for contracts that are within the scope of other authoritative literature. Under ASC 606, we recognize revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy a performance obligation. We apply the five-step model to arrangements that meet the definition of a contract under ASC 606 including when it is probable that we will collect the consideration we are entitled to in exchange for goods or services we transfer to the customer. At contract inception, we assess the goods or services promised within each contract and determine those that are performance obligations, and assesses whether each promised good or service is distinct. We recognize revenue for the amount of the transaction price that is allocated to the respective performance obligation as the performance obligation is satisfied. License and Development Services Arrangements We recognize license and contract revenue under license and development services arrangements that are within the scope of ASC 606. The terms of these agreements may contain multiple performance obligations, which may include licenses and research and development activities. We evaluate these agreements under ASC 606 to determine distinct performance obligations. Prior to recognizing revenue, we make estimates of the transaction price, including any variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that there will not be a significant reversal in the amount of cumulative revenue recognized and when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include nonrefundable upfront license fees, payments for research and development activities, reimbursement of certain third-party costs, payments based upon the achievement of specified milestones, and royalty payments based on product sales derived from the collaboration. If there are multiple, distinct performance obligations, we allocate the transaction price to each distinct performance obligation based on its relative standalone selling price. Revenue is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure in accordance with ASC-340-40, Other Assets and Deferred Costs: Contracts with Customers . Research and Development Expenses Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development . Research and development expenses include related salaries and benefits, clinical trial and related manufacturing costs, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaboration research and development and include activities such as product registries and investigator-sponsored trials. In instances where we enter into agreements with third parties for research and development activities, we may prepay fees for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Other types of arrangements with third parties may be fixed fee or fee for service, and may include monthly payments or payments upon completion of milestones or receipt of deliverables. We expense upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use. Foreign Currency Translation and Transaction Gains and Losses We record foreign currency translation adjustments and transaction gains and losses in accordance with ASC 830, Foreign Currency Matters. For operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss, but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of stockholders’ equity, except for intercompany transactions that are of a short-term nature with entities that are consolidated, combined or accounted for by the equity method in our consolidated financial statements. We have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of operations related to the recurring measurement and settlement of such transactions. During the year ended December 31, 2019 , in connection with the dissolution of CTILS, a gain in the amount of $1.3 million was released from the cumulative foreign currency translation adjustment account and recorded in Other non-operating income in the consolidated statement of operations in accordance with ASC 830, Foreign Currency Matters. See Note 9. Other Comprehensive Loss for additional details. During the year ended December 31, 2018 , the intercompany balance due from CTILS was considered to be of a long-term nature, and as such, an unrealized foreign exchange loss of $1.5 million was recorded in the cumulative foreign currency translation adjustment account. As of December 31, 2018 , such intercompany balance due from CTILS was €28.7 million (or $32.8 million upon conversion from euros as of December 31, 2018 ). Income Taxes We record a tax provision for the anticipated tax consequences of our results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates in effect for the years in which those tax assets and liabilities are expected to be realized or settled. We provide a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. Net Loss per Share Basic net loss per common share is calculated based on the net loss attributable to common stockholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per common share excludes the potential conversion of all dilutive convertible securities, such as convertible preferred stock, using the if-converted method, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, using the treasury stock method, as their inclusion would have an anti-dilutive effect. Recently Adopted Accounting Standards In February 2016, the FASB issued ASC 842 - Leases , which requires lessees to recognize virtually all of their leases (other than leases that meet the definition of a short-term lease) on the balance sheet. On January 1, 2019, we adopted ASC 842 using the modified retrospective approach with a cumulative-effect adjustment as of January 1, 2019 in accordance with ASU No. 2018-11, Leases (Topic 842) - Targeted Improvements . Prior period amounts are not adjusted and continue to be reported under previous lease guidance, ASC 840 - Leases . We have performed an evaluation of our contracts with customers and suppliers in accordance with ASC 842 and have determined that the agreements for our office space, parking and office equipment contained a lease. All identified leases are classified as operating leases. We had no finance or capital leases as of and for the years ended December 31, 2019 and 2018 . We also elected a package of practical expedients permitted under the transition guidance within the new standard. The impact of the adoption of ASC 842 on our consolidated balance sheet as of January 1, 2019 was as follows (in thousands): December 31, 2018 Adjustments due to adoption of ASC 842 January 1, 2019 Right-of-use assets $ — $ 4,208 $ 4,208 Lease liabilities, current $ — $ 1,687 $ 1,687 Lease liabilities, non-current $ — $ 4,946 $ 4,946 Deferred rent, current $ 893 $ (893 ) $ — Deferred rent, non-current $ 2,157 $ (2,157 ) $ — Accumulated deficit $ (2,224,746 ) $ 1,196 $ (2,223,550 ) The adoption of the standard did not materially impact our consolidated statements of operations or consolidated statements of cash flows. See Note 5. Leases for further details about our leases. In June 2018, the FASB issued new accounting guidance which simplifies the accounting for share-based payments granted to nonemployees for goods and services by aligning it with the accounting for share-based payments to employees, with certain exceptions. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We adopted this guidance on January 1, 2019. The adoption of this accounting guidance did not have a material impact on our consolidated financial statements. In December 2019, the FASB issued new accounting guidance which modifies ASC 740 - Income Taxes to simplify the accounting for income taxes. These modifications include, among other things, elimination of certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption is permitted. We early adopted this guidance on January 1, 2019. The adoption of this accounting guidance did not have a material impact on our consolidated financial statements. See Note 17. Income Taxes for further details. Recently Issued Accounting Standards In June 2016, the FASB issued new accounting guidance which amends the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. We do not expect the adoption of this accounting guidance to have a material impact on our consolidated financial statements. In August 2018, the FASB issued new accounting guidance which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We do not expect the adoption of this accounting guidance to have a material impact on our consolidated financial statements. Although there were several other new accounting pronouncements issued or proposed by the FASB, we do not believe any of these have had or will have material impact on our consolidated financial statements. Reclassifications Certain prior year items have been reclassified to conform to current year presentation.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	2. Property and Equipment Property and equipment are composed of the following as of December 31, 2019 and 2018 (in thousands): 2019 2018 Furniture and office equipment $ 2,872 $ 4,445 Leasehold improvements 5,140 5,168 Lab equipment — 63 8,012 9,676 Less: accumulated depreciation and amortization (6,777 ) (7,883 ) Property and equipment, net $ 1,235 $ 1,793 Depreciation expense for the years ended December 31, 2019 and 2018 was $0.5 million and $0.6 million , respectively.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	3. Other Assets Other assets consisted of the following as of December 31, 2019 and 2018 (in thousands): 2019 2018 Right-of-use assets $ 3,379 $ — Italian VAT receivables 4,390 4,480 Italian VAT deposit 483 493 Clinical trial deposits 720 — Refundable security deposit 194 194 Other 299 380 Other assets $ 9,465 $ 5,547 On January 1, 2019, we adopted ASC 842 - Leases and recorded right-of-use assets for our operating leases. See Note 1. Description of Business and Summary of Significant Accounting Policies - Recently Adopted Accounting Standards and Note 5. Leases for further details. For details regarding our Italian VAT receivables and Italian VAT deposit, see Note 1. Description of Business and Summary of Significant Accounting Policies - Italian Value Added Tax Receivable and Note 16. Commitments and Contingencies .

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Expenses	4. Accrued Expenses Accrued expenses consisted of the following as of December 31, 2019 and 2018 (in thousands): 2019 2018 Clinical trial expenses $ 7,920 $ 6,573 Employee compensation and related expenses 2,851 4,216 Restructuring expenses — 660 Manufacturing expenses 228 458 Other 607 945 Total accrued expenses $ 11,606 $ 12,852

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	5. Leases In January 2012 , we entered into an agreement with Selig Holdings Company LLC, or Selig, to lease approximately 66,000 square feet of office space in Seattle, Washington for a term of 10 years , commencing May 2012 . We have two five -year options to extend the term of the lease at a market rate determined according to the lease. We also had an option to early terminate the lease after the fifth anniversary from the commencement date. We were provided with a total of $3.9 million for certain tenant improvements and other lease incentives. The options to extend or terminate the lease were not considered in the determination of the right-of-use asset and the lease liability as we did not consider it reasonably certain that we would exercise such options. We also lease parking space and certain office equipment. We have elected not to separate a non-lease component from a lease component for these leases. In December 2017 , we entered into an agreement to sublease approximately 44,000 square feet of our office space. No payments were due through May 2018 , after which monthly rent is due through the sublease termination date in April 2022 . The operating lease for our office space includes common area maintenance services provided by Selig, which are considered a non-lease component. Since the payments for these services are based on the actual costs incurred by Selig in providing the services, we consider these payments as variable lease expenses. The components of lease expense, which were included in our consolidated statements of operations, were as follows (in thousands): Year Ended December 31, 2019 2018 Operating lease expense $ 1,696 $ 1,384 Variable lease expense 178 195 Sublease income (1,247 ) (1,247 ) Total lease expense, net $ 627 $ 332 The balance sheet classification of operating lease right-of-use assets and operating lease liabilities were as follows (in thousands): December 31, 2019 Right-of-use assets (included in Other assets ) $ 3,379 Lease liabilities, current (included in Other current liabilities ) $ 1,953 Lease liabilities, non-current (included in Other liabilities ) 2,993 Total lease liabilities $ 4,946 As of December 31, 2019 , the maturities of operating lease liabilities were as follows (in thousands): Operating Sublease Lease Payments Rental Receipts Net 2020 $ 2,443 $ (1,410 ) $ 1,033 2021 2,438 (1,454 ) 984 2022 820 (499 ) 321 Thereafter — — — Total payments 5,701 $ (3,363 ) $ 2,338 Less imputed interest (755 ) Total lease liabilities $ 4,946 Supplemental information relating to our operating leases is as follows (in thousands): December 31, 2019 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities $ 2,391 Weighted-average remaining lease term of operating leases (years) 2.31 Weighted-average discount rate of operating leases 12.4 %

Other Liabilities

Other Liabilities	12 Months Ended
	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Other Liabilities	6. Other Liabilities Other liabilities consisted of the following as of December 31, 2019 and 2018 (in thousands): 2019 2018 Lease liabilities, non-current $ 2,993 $ — Deferred rent, non-current — 2,157 Other long-term obligations 2,414 2,414 Total other liabilities $ 5,407 $ 4,571 On January 1, 2019, we adopted ASC 842 - Leases and recorded lease liabilities and corresponding right-of-use assets for our operating leases. Deferred rent, less current portion as of December 31, 2018 included amounts related to lease incentives associated with our operating lease for office space. Under ASC 842, such lease incentives are accounted for as a reduction to the right-of-use asset balance. See Note 1. Description of Business and Summary of Significant Accounting Policies - Recently Adopted Accounting Standards and Note 5. Leases for further details. Other long-term obligations as of December 31, 2019 and 2018 included a fee in the amount of $1.4 million payable to Silicon Valley Bank. See Note 7. Long-term Debt for additional information.

Long-term Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Long-term Debt	7. Long-term Debt In November 2017 , we entered into a Loan and Security Agreement with Silicon Valley Bank, or SVB, for a secured term loan of up to $18.0 million . The first $16.0 million of the term loan was funded in November 2017 . We had an option to borrow an additional $2.0 million , which option expired unexercised on July 31, 2018. The loan proceeds were used to repay in full all outstanding indebtedness under a prior loan and security agreement and to fund our general business requirements. The term loan is repayable over 36 months after an initial interest-only period of 12 months after closing. The interest rate on the term loan floats at a rate per annum equal to the greater of 2.5 percent above the prime rate and 6.75 percent . We may elect to prepay some or all of the loan balance at any time subject to a prepayment fee. A back-end fee in the amount of 9 percent of the total principal amount funded to us is payable to SVB on the date on which the term loan is paid or becomes due and payable in full. The loan obligations are secured by a first priority security interest on substantially all of our personal property except our intellectual property and subject to certain other exceptions. We also issued warrants to SVB and Life Science Loans II, LLC in November 2017 , pursuant to a participation arrangement among SVB, Loan Manager II, LLC and Life Science Loans II, LLC, to purchase up to 190,140 shares of our common stock. Warrants have an initial exercise price of $2.84 per share of our common stock and will expire on November 28, 2027 . The back-end fee in the amount of $1.4 million and the warrants, which had a fair value of $0.5 million on the date of grant, were together recorded as a $1.9 million debt discount. In connection with the Loan and Security Agreement, we also recorded debt issuance costs of $0.1 million . As of December 31, 2019 , $0.9 million of the original debt discount and $0.1 million of the debt issuance costs remained unamortized. The outstanding principal balance on the term loan was $10.2 million as of December 31, 2019 . As of December 31, 2019 , the scheduled principal and interest payments (based on the interest rate of 7.25 percent as of December 31, 2019 ) as well as the back-end fee described above are as follows: Principal Interest Back-end fee Total 2020 $ 5,333 $ 573 $ — $ 5,906 2021 4,889 180 1,440 6,509 Thereafter — — — — Total scheduled payments $ 10,222 $ 753 $ 1,440 $ 12,415 Less: debt discount and issuance costs $ (955 ) Less: current portion of long-term debt $ (4,812 ) Long-term debt $ 4,455

Equity Transactions

Equity Transactions	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Equity Transactions	8. Equity Transactions Preferred Stock In February 2018 , 575 shares of our Series N Preferred Stock owned by BVF Partners L.P., or BVF, along with 8.0 million shares of our common stock owned by BVF were exchanged for 12,575 shares of our Series O Preferred Stock. For the year ended December 31, 2018 , we recognized $0.1 million in deemed dividends on preferred stock related to the beneficial conversion feature on the Series O Preferred Stock. There were 12,575 shares of Series O Preferred Stock outstanding as of December 31, 2019 and 2018 . BVF is an existing stockholder of the Company, and was one of our investors in the Common Stock offering in February 2018 discussed below. See Note 15. Related Party Transactions for further details. Each share of Series O Preferred Stock is convertible at the option of the holder (subject to certain limitations) into shares of common stock at a conversion price of $3.00 per share of common stock. Each share of Series O Preferred Stock is entitled to a liquidation preference equal to the initial stated value of $2,000 per share, plus any declared and unpaid dividends, and any other payments that may be due on such shares, before any distribution of assets may be made to holders of capital stock ranking junior to the Series O Preferred Stock. The Series O Preferred Stock is not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series O Preferred Stock has no voting rights, except as otherwise expressly provided in the certificate of incorporation of CTI or as otherwise required by law. Common Stock In February 2018, we offered and sold 23.0 million shares of our common stock, referred to as the Offering. The price to the public in this Offering was $3.00 per share of common stock. The gross proceeds from the Offering were $69.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $4.8 million . In November 2019, we entered into an Open Sale Agreement with Jefferies LLC, referred to as the Jefferies Sale Agreement, to sell shares of our common stock, having aggregate sales proceeds of up to $15.0 million , from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent. Under the terms of the Jefferies Sale Agreement, we will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Jefferies Sale Agreement, Jefferies may sell the shares by methods deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, including sales made directly on The Nasdaq Capital Market or on any other existing trading market for the common stock. Jefferies will use commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices, applicable state and federal laws, rules and regulations and the rules of The Nasdaq Stock Market LLC. We and Jefferies may each terminate the Jefferies Sale Agreement at any time upon one trading day’s prior notice. We may also sell shares to Jefferies acting as principal for Jefferies' own account. The compensation to Jefferies for sales of our common stock will be an amount equal to 3% of the gross proceeds of any shares of common stock sold under the Jefferies Sale Agreement. We have no obligation to sell any shares under the Jefferies Sale Agreement, and may at any time suspend solicitation and offers under the Jefferies Sale Agreement. We recorded financing costs of $0.2 million in Selling, general and administrative expenses in connection with the Jefferies Sale Agreement for the year ended December 31, 2019 . No shares of common stock were sold under the Jefferies Sale Agreement during the year ended December 31, 2019 . Rights Offering In March 2020, we completed our rights offering. See Note 18. Subsequent Events for further details. Common Stock Authorized In May 2018 , the Company's certificate of incorporation was amended to increase the total number of authorized shares of common stock from 81.5 million to 101.5 million . In May 2019 , the Company's certificate of incorporation was amended to increase the total number of authorized shares of common stock from 101.5 million to 131.5 million . Common Stock Reserved As of December 31, 2019 , we had 131.5 million authorized shares of common stock, of which 58.0 million shares were issued and outstanding, and 21.4 million shares were reserved for future issuances as follows (in thousands): Equity incentive plans 11,211 Option agreement with Adam R. Craig 1,120 Common stock purchase warrants 514 Series O convertible preferred stock 8,383 Employee stock purchase plan 176 Total common stock reserved 21,404 Warrants Warrants to purchase up to 29,239 shares of our common stock with an exercise price of $17.10 per share, issued in connection with the Third Amendment to the Loan Agreement with Hercules Technology Growth Capital, Inc. in 2015, were outstanding and exercisable as of December 31, 2019 . Warrants to purchase up to 190,140 shares of our common stock with an exercise price of $2.84 per share, issued in connection with the Loan and Security Agreement with SVB in 2017, were outstanding as of December 31, 2019 . Of this amount, warrants to purchase up to 169,014 shares of our common stock were exercisable as of December 31, 2019 . Warrants to purchase up to 294,117 shares of our common stock with an exercise price of $1.70 per share, which were issued to a vendor in 2018 as part of compensation for services, were outstanding but remained unexercisable as of December 31, 2019 .

Other Comprehensive Loss

Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Other Comprehensive Loss	9. Other Comprehensive Loss Total accumulated other comprehensive loss consisted of the following (in thousands): Net Unrealized (Loss) Gain on Available-For-Sale Securities Foreign Currency Translation Adjustments (1) Unrealized Foreign Exchange Loss on Intercompany Balance (1) Accumulated Other Comprehensive Loss December 31, 2018 $ (14 ) $ (9,672 ) $ (957 ) $ (10,643 ) Current period other comprehensive income (loss) 16 (2,323 ) 957 (1,350 ) December 31, 2019 $ 2 $ (11,995 ) $ — $ (11,993 ) (1) In accordance with ASC 830, Foreign Currency Matters , the current period change includes a release of cumulative translation adjustment in the amount of $1.3 million upon dissolution of CTILS, our foreign subsidiary, which was recognized in Other non-operating income in the consolidated statement of operations for the year ended December 31, 2019 .

Collaboration, Licensing and Mi

Collaboration, Licensing and Milestone Agreements	12 Months Ended
	Dec. 31, 2019
Collaborations [Abstract]
Collaboration, Licensing and Milestone Agreements	10. Collaboration, Licensing and Milestone Agreements Servier In September 2014 , we entered into an Exclusive License and Collaboration Agreement, or the Original Agreement, with Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively, Servier. In April 2017 , we entered into an Amended and Restated Exclusive License and Collaboration Agreement, or the Restated Agreement, with Servier, pursuant to which the Original Agreement was amended and restated in its entirety. Under the Restated Agreement, we granted Servier an exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products, or Licensed Products, outside of the United States (and its territories and possessions). In February 2019, we entered into a Termination and Transfer Agreement, or the Servier Termination Agreement, among, on the one hand, the Company and its subsidiary, CTILS, and, on the other hand, Servier, which terminated the Restated Agreement. Under the Servier Termination Agreement, we were responsible for non-U.S. pharmacovigilance for PIXUVRI (pixantrone), the submission of a marketing authorization application for PIXUVRI and wind down of the PIX306 clinical trial during a transition period. Servier reimbursed us €620,000 (of which, €65,000 was reimbursed and recognized as license and contract revenue in 2018 ) for costs incurred in connection with transition period activities, and as such we recognized $0.6 million of license and contract revenue related to the transition period activities during the year ended December 31, 2019 . In April 2019, Servier announced that the EMA's Committee for Medicinal Products for Human Use, or CHMP, issued a positive opinion for PIXUVRI to convert its conditional approval into a standard marketing authorization as a single agent for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, and in June 2019, the European Commission adopted the decision to grant non-conditional marketing authorization for PIXUVRI. Pursuant to the Servier Termination Agreement, we agreed to transfer and assign all of our rights and responsibilities for PIXUVRI globally to Servier pursuant to an asset purchase agreement. In August 2019, we entered into an asset purchase agreement, which was amended and restated in September 2019, or the Asset Purchase Agreement. The Asset Purchase Agreement required, among other things, Servier to pay us €2.0 million and assume responsibility for all of the obligations related to PIXUVRI, including the Company’s remaining royalty payments to Novartis International Pharmaceutical Ltd. and the University of Vermont. For the year ended December 31, 2019 , we recognized $2.2 million of license and contract revenue related to the Asset Purchase Agreement, and all of our rights and responsibilities for PIXUVRI were transferred and assigned globally to Servier pursuant to the Asset Purchase Agreement. Teva Pursuant to an acquisition agreement entered into with Cephalon, Inc., or Cephalon, in June 2005, we have the right to receive up to $100.0 million in payments upon achievement of specified sales and development milestones related to TRISENOX. Cephalon was subsequently acquired by Teva Pharmaceutical Industries Ltd., or Teva. As of December 31, 2019 , we had earned $60.0 million of such potential milestone payments as a result of having achieved certain milestones. For the year ended December 31, 2018 , we received $10.0 million from Teva upon the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia. We also earned $10.0 million upon the achievement of worldwide net sales milestones of TRISENOX during the year ended December 31, 2018 . The achievement of the remaining milestones is uncertain at this time. Baxalta In November 2013 , we entered into the Pacritinib License Agreement with Baxter for the development and commercialization of pacritinib for use in oncology and potentially additional therapeutic areas. Baxter assigned its rights and obligations under the Pacritinib License Agreement to Baxalta. Under the Pacritinib License Agreement, we granted to Baxter an exclusive, worldwide (subject to our certain co-promotion rights in the United States), royalty-bearing, non-transferable, and (under certain circumstances outside of the United States) sub-licensable license to our know-how and patents relating to pacritinib. In October 2016 , we entered into the Asset Return and Termination Agreement, or the Baxalta Termination Agreement, with Baxalta. Pursuant to the Baxalta Termination Agreement, the Pacritinib License Agreement was terminated in its entirety (other than with respect to certain customary provisions that survive termination, including those pertaining to confidentiality and indemnification), the Pacritinib License Agreement has no further force or effect, and all rights and obligations of the Company and Baxalta under the Pacritinib License Agreement were terminated. In October 2016 , we resumed primary responsibility for the development and commercialization of pacritinib as a result of the Baxalta Termination Agreement and are no longer eligible to receive cost sharing or milestone payments for pacritinib’s development from Baxalta. In addition, under the Baxalta Termination Agreement, we are required to make a milestone payment to Baxalta in the amount of approximately $10.3 million upon the first regulatory approval or any pricing and reimbursement approvals of a product containing pacritinib. Novartis In January 2014 , we entered into a Termination Agreement, or the Novartis Termination Agreement, with Novartis to reacquire the rights to PIXUVRI and Opaxio, or collectively, the Compounds, previously granted to Novartis under our License and Co-Development Agreement with Novartis, as amended, or the Original Novartis Agreement. Pursuant to the Novartis Termination Agreement, the Original Novartis Agreement was terminated in its entirety, other than with respect to certain customary provisions, including those pertaining to confidentiality and indemnification, which survive termination. Under the Novartis Termination Agreement, we agreed not to transfer, license, sublicense or otherwise grant rights with respect to intellectual property of the Compounds unless the transferee/licensee/sublicensee agrees to be bound by the terms of the Novartis Termination Agreement. We also agreed to provide potential payments to Novartis, including a percentage ranging from the low double-digits to the mid-teens, of any consideration received by us or our affiliates in connection with any transfer, license, sublicense or other grant of rights with respect to intellectual property of the Compounds, provided that such payments would not exceed certain prescribed ceilings in the low-single digit millions. Novartis is entitled to receive potential payments of up to $16.6 million upon the achievement of certain sales milestones of the Compounds. Novartis is also eligible to receive tiered low single-digit percentage royalty payments for the first several hundred million in annual net sales, and ten percent royalty payments thereafter based on annual net sales of each Compound, subject to reduction in the event generic drugs are introduced and sold by a third party, causing the sale of the Compounds to fall by a percentage in the high double-digits. Notwithstanding the foregoing, royalty payments for the Compounds are subject to certain minimum floor percentages in the low single-digits. During the year ended December 31, 2019 , pursuant to the Asset Purchase Agreement discussed in Servier above, all of our responsibilities and obligations related to PIXUVRI under the Novartis Termination Agreement were fully transferred and assigned to Servier. University of Vermont In March 1995, the University of Vermont, or UVM, entered into an agreement, or the UVM Agreement, which, as amended in March 2000, grants us an exclusive, sublicensable license for the rights to PIXUVRI. Pursuant to the UVM Agreement, we acquired the rights to make, have made, sell and use PIXUVRI. We were obligated to make royalty payments to UVM that ranged from low-single digits to mid-single digits as a percentage of net sales. The higher royalty rate is payable for net sales in countries where specified UVM licensed patents exist, or where we have obtained orphan drug protection, until such UVM patents or such protection no longer exists. For a period of ten years after first commercialization of PIXUVRI, the lower royalty rate is payable for net sales in such countries after expiration of the designated UVM patents or loss of orphan drug protection, and in all other countries without such specified UVM patents or orphan drug protection. Unless otherwise terminated, the term of the UVM Agreement continues for the life of the licensed patents in those countries in which a licensed patent exists, and continues for ten years after the first sale of PIXUVRI in those countries where no such patents exist. During the year ended December 31, 2019 , pursuant to the Asset Purchase Agreement discussed in Servier above, all of our responsibilities and obligations related to PIXUVRI under the UVM Agreement were fully transferred and assigned to Servier. S*BIO Pte Ltd. We acquired the compounds SB1518 (which is referred to as “pacritinib”) and SB1578, which inhibit JAK2 and FLT3, from S*BIO Pte Ltd., or S*BIO, in May 2012 . Under our agreement with S*BIO, we are required to make milestone payments to S*BIO up to an aggregate amount of $132.5 million if certain United States, EU and Japanese regulatory approvals are obtained or if certain worldwide net sales thresholds are met in connection with any pharmaceutical product containing or comprising any compound that we acquired from S*BIO for use for specific diseases, infections or other conditions. At our election, we may pay up to 50% of any milestone payments to S*BIO through the issuance of shares of our common stock or shares of our preferred stock convertible into our common stock. S*BIO will also be entitled to receive royalty payments from us at incremental rates in the low single-digits based on certain worldwide net sales thresholds on a product-by-product and country-by-country basis. Vernalis We entered into an amended and restated exclusive license agreement with Vernalis (R&D) Limited, or Vernalis, in October 2014, or the Vernalis License Agreement, for the exclusive worldwide right to use certain patents and other intellectual property rights to develop, market and commercialize tosedostat and certain other compounds. Under the Vernalis License Agreement, we have agreed to make tiered royalty payments of no more than a high single-digit percentage of net sales of products containing licensed compounds, with such obligation to continue on a country-by-country basis for the longer of ten years following commercial launch or the expiry of relevant patent claims. The Vernalis License Agreement will terminate when the royalty obligations expire, although the parties have early termination rights under certain circumstances, including the following: (1) we have the right to terminate, with three months’ notice, upon the belief that the continued development of tosedostat or any of the other licensed compounds is not commercially viable, (2) Vernalis has the right to terminate in the event of our uncured failure to pay sums due, and (3) either party has the right to terminate in the event of the other party’s uncured material breach or insolvency. We have ceased development of tosedostat and do not anticipate incurring additional material expenses related to this terminated program. Other Agreements We have several agreements with contract research organizations, third-party manufacturers and distributors which have durations of greater than one year for the development and distribution of certain of our compounds.

Restructuring Activities

Restructuring Activities	12 Months Ended
	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Restructuring Activities	11. Restructuring Activities In December 2018, we announced a restructuring plan to improve efficiencies and reduce costs within the Company, which impacted a total of 21 positions. The restructuring activities were substantially completed as of March 31, 2019 , and we incurred total restructuring expenses of approximately $1.5 million , of which $0.8 million had been incurred during the year ended December 31, 2019 . The following table summarizes the accrual balance and utilization for the year ended December 31, 2019 (in thousands): Employee separation costs Restructuring accruals - December 31, 2018 $ 660 Restructuring expenses 794 Cash payments (1,454 ) Restructuring accruals - December 31, 2019 $ —

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	12. Share-Based Compensation Share-Based Compensation Expense Share-based compensation expense for all share-based payment awards made to employees and directors is measured based on the grant-date fair value estimated in accordance with U.S. GAAP. We recognize share-based compensation using the straight-line, single-award method based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Share-based compensation is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. During the years ended December 31, 2019 and 2018 , we recognized share-based compensation expense which consisted of the following types of awards (in thousands): 2019 2018 Restricted stock — 102 Options 5,166 6,267 Total share-based compensation expense $ 5,166 $ 6,369 The following table summarizes share-based compensation expense for the years ended December 31, 2019 and 2018 , which was allocated as follows (in thousands): 2019 2018 Research and development $ 506 $ 1,950 Selling, general and administrative 4,660 4,419 Total share-based compensation expense $ 5,166 $ 6,369 Share-based compensation had a $5.2 million and $6.4 million effect on our net loss attributable to common stockholders for the years ended December 31, 2019 and 2018 , respectively. It had no effect on cash flows from operating activities for the periods presented; however, during the year ended December 31, 2018 , we made a payment of $21,000 relating to 5,800 shares of our common stock withheld upon vesting of employee restricted stock awards based on taxes owed by employees upon vesting, which impacted cash flows used in financing activities. We made no such payments during the year ended December 31, 2019 as no shares of restricted stock awards vested during the year ended December 31, 2019 . As of December 31, 2019 , unrecognized compensation cost related to unvested stock options amounted to $4.7 million , which will be recognized over the remaining weighted-average requisite service period of 1.73 years . There was no unrecognized compensation cost related to unvested restricted stock awards (other than performance-based awards) as of December 31, 2019 . The unrecognized compensation cost related to unvested options and unvested restricted stock does not include the value of performance-based awards since we do not believe vesting of such awards is probable at this time. For the years ended December 31, 2019 and 2018 , no tax benefits were attributed to share-based compensation expense because a valuation allowance was maintained for all net deferred tax assets. Stock Plans In May 2017 , the Company's 2017 Equity Incentive Plan, or the 2017 Plan, was approved by the Company's shareholders, and no additional awards will be granted under the 2015 Equity Incentive Plan, or the 2015 Plan. The Company's 2007 Employee Stock Purchase Plan, as amended and restated in August 2009 and September 2015, or the Purchase Plan, was amended in September 2015 to increase the maximum number of shares of the Company’s common stock authorized for issuance by 0.2 million shares. Refer to Employee Stock Purchase Plan below for further details. Pursuant to our 2017 Plan, we may grant the following types of incentive awards: (1) stock options, including incentive stock options and non-qualified stock options, (2) stock appreciation rights, (3) restricted stock, (4) restricted stock units and (5) cash awards. The 2017 Plan is administered by the Compensation Committee of our Board, which has the discretion to determine the employees and consultants who shall be granted incentive awards. The Board retained sole authority under the 2017 Plan with respect to non-employee directors’ awards, although the Compensation Committee has authority under its charter to make recommendations to the Board concerning such awards. Options expire 10 years from the date of grant, subject to the recipients continued service to the Company. As of December 31, 2019 , 13.6 million shares were authorized for issuance under equity incentive plans, of which 1.0 million shares of common stock were available for future grants under the 2017 Plan. Stock Options Fair value for stock options was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions: Year Ended December 31, 2019 2018 Risk-free interest rate 2.3 % 2.9 % Expected dividend yield None None Expected life (in years) 4.4 5.4 Volatility 89 % 82 % The risk-free interest rate used in the Black-Scholes valuation method is based on the implied yield currently available for U.S. Treasury securities at maturity with an equivalent term. We have not declared or paid dividends on our common stock and do not currently expect to do so in the future. The expected term of options represents the period that our options are expected to be outstanding and was determined based on historical weighted average holding periods and projected holding periods for the remaining unexercised options. Consideration was given to the contractual terms of our options, vesting schedules and expectations of future employee behavior. Expected volatility is based on the annualized daily historical volatility, including consideration of the implied volatility and market prices of traded options for comparable entities within our industry. Our stock price volatility and option lives, both of which impact the fair value of options calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option, involve management’s best estimates. As we recognize compensation expense for only the portion of options expected to vest, we apply estimated forfeiture rates that we derive from historical employee termination behavior. If the actual number of forfeitures differs from our estimates, additional adjustments to compensation expense may be required in future periods. The following table summarizes stock option activity for all of our stock option plans: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Thousands) Outstanding at December 31, 2018 (2,597,000 exercisable) 7,219,000 $ 4.08 Granted 5,307,000 $ 0.91 Exercised — $ — Forfeited (1,115,000 ) $ 2.16 Cancelled and expired (457,000 ) $ 8.35 Outstanding at December 31, 2019 (4,047,000 exercisable) 10,954,000 $ 2.56 8.3 $ 3,504 Vested or expected to vest at December 31, 2019 10,510,000 $ 2.61 8.3 $ 3,252 Exercisable at December 31, 2019 4,047,000 $ 4.39 7.2 $ 6 The weighted average exercise price of options exercisable at December 31, 2019 and 2018 was $4.39 and $5.49 , respectively. The weighted average grant-date fair value of options granted during 2019 and 2018 was $0.60 and $2.09 per option, respectively. The number of options vested or expected to vest at December 31, 2019 does not include 4,000 performance-based options with the weighted average exercise price of $22.35 since the achievement of such performance-based milestone was not deemed probable as of December 31, 2019 . In March 2017 , Dr. Adam R. Craig, our President and CEO, was granted stock options to purchase 1.2 million shares of common stock at an exercise price of $4.24 per share. The stock options have a maximum term of ten years and vest in six equal semi-annual installments over the three -year period beginning March 20, 2017, subject to his continued employment through the applicable vesting dates and acceleration under certain circumstances. The stock options were granted in connection with his entering into employment with the Company as President and CEO. A portion of the stock options covering 80,000 shares were granted under the 2015 Plan. The balance of such stock options was granted in accordance with Nasdaq Listing Rule 5635(c)(4). Restricted Stock No shares of restricted stock awards were issued in 2019 or 2018 . Additionally, 8,000 and 15,000 shares of restricted stock awards were cancelled during 2019 and 2018 , respectively. The total fair value of restricted stock awards vested during the year ended December 31, 2018 was $0.1 million . No shares of restricted stock awards vested during the year ended December 31, 2019 . A summary of the status of nonvested restricted stock awards as of December 31, 2019 and 2018 and changes during the periods then ended, is presented below: Nonvested Shares Weighted Average Grant-Date Fair Value Per Share Nonvested at December 31, 2017 63,000 $ 15.93 Issued — $ — Vested (35,000 ) $ 12.00 Forfeited (15,000 ) $ 16.12 Nonvested at December 31, 2018 13,000 $ 26.23 Issued — $ — Vested — $ — Forfeited (8,000 ) $ 19.12 Nonvested at December 31, 2019 5,000 $ 38.90 All nonvested restricted stock outstanding as of December 31, 2019 was performance-based awards. We do not believe vesting of such awards is probable at this time. Employee Stock Purchase Plan Under the Purchase Plan, eligible employees may purchase a limited number of shares of our common stock at 85% of the lower of the subscription date fair market value and the purchase date fair market value. There are two six-month offerings per year. Under the Purchase Plan, we issued approximately 2,000 and 5,000 shares of our common stock to employees during the years ended December 31, 2019 and 2018 , respectively. There are 0.2 million shares of common stock authorized under the Purchase Plan and approximately 0.2 million shares are reserved for future purchases as of December 31, 2019 .

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Employee Benefit Plans	13. Employee Benefit Plans Our U.S. employees participate in the CTI BioPharma Corp. 401(k) Plan whereby eligible employees may defer up to 80% of their compensation, up to the annual maximum allowed by the Internal Revenue Service. We may make discretionary matching contributions based on certain plan provisions. We recorded $0.1 million and $0.2 million related to discretionary matching contributions during the year ended December 31, 2019 and 2018 , respectively.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Net Loss Per Share	14. Net Loss Per Share Basic net loss per share is calculated based on the net loss attributable to common stockholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per share excludes the potential conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, as their inclusion would have an anti-dilutive effect. Accordingly, diluted net loss per share is the same as basic net loss per share . The computation of net loss per share is as follows (in thousands, except per share amounts): Year Ended December 31, 2019 2018 Net loss attributable to common stockholders $ (40,020 ) $ (29,400 ) Basic and diluted: Weighted average shares outstanding 57,980 56,106 Less: weighted average restricted shares outstanding (6 ) (33 ) Shares used in calculation of basic and diluted net loss per common share 57,974 56,073 Net loss per common share: Basic and diluted $ (0.69 ) $ (0.52 ) Common shares underlying equity awards, warrants and convertible preferred stock aggregating 18.9 million shares and 15.3 million shares for the years ended December 31, 2019 and 2018 , respectively, prior to the application of the treasury stock method, have been excluded from the calculation of diluted net loss per share because they were anti-dilutive.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions Aequus We have a majority ownership interest in Aequus. In May 2007 , we entered into a license agreement with Aequus whereby Aequus gained rights to our Genetic Polymer™ technology. We also entered into an agreement to fund Aequus in exchange for a convertible promissory note. In March 2017 , we and Aequus entered into a License and Promissory Note Termination Agreement and a Note Cancellation Agreement, pursuant to which (1) all of the then-outstanding principal, plus all accrued and unpaid interest, approximately $13.7 million in total, was cancelled and terminated, (2) our license agreement with Aequus was terminated, (3) all obligations to Aequus were terminated with the exception of providing additional funding of up to $347,500 to Aequus, and (4) Aequus agreed to pay us a) 20% of milestone and similar payments, up to a maximum amount of $20.0 million , and b) royalties, on a product-by-product and county-by country basis, of 5% of net sales of certain ACTH Products being developed by Aequus. The additional funding of $347,500 had been provided in full as of September 30, 2017 . Payments from Aequus are due the later of (1) expiration of the last to expire valid patent claim that claims the ACTH Product, or (2) ten years from the first commercial sale of the applicable ACTH Product. We have the right to terminate the License and Promissory Note Termination Agreement and require Aequus to assign all ACTH Product related assets to us without further compensation to Aequus if Aequus does not file an Investigational New Drug Application for an ACTH Product with the FDA by September 6, 2019 . Aequus did not file an Investigational New Drug Application by September 6, 2019; however, we have not exercised such right and have not requested Aequus to assign all ACTH Product related assets to us. BVF Partners L.P. In February 2018 , in connection with the public offering of common stock (also discussed in Note 8. Equity Transactions ) , BVF purchased 6.3 million shares of our common stock. In addition, BVF exchanged 8.0 million shares of our common stock owned by BVF and 575 shares of our Series N Preferred Stock owned by BVF for 12,575 shares of our Series O Preferred Stock. As of December 31, 2019 and 2018 , BVF beneficially owned approximately 12.0% of our outstanding common stock. Matthew D. Perry, a member of our Board, is the President of BVF and portfolio manager for the underlying funds managed by the firm. In March 2020 , in connection with our rights offering as discussed in Note 18. Subsequent Events , BVF purchased a total of 3,047 shares of our Series X Preferred Stock, which are convertible into 30.5 million shares of our common stock. As of the date of the filing of this Annual Report on Form 10-K, no shares of Series X Preferred Stock owned by BVF have been converted into our common stock.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Commitments See Note 5. Leases and Note 7. Long-term Debt for scheduled lease and debt payments. In addition, certain of our licensing agreements obligate us to make payments upon achievement of milestones and pay a royalty on net sales of products utilizing licensed compounds. See Note 10. Collaboration, Licensing and Milestone Agreements for further details. Purchase commitments relating to clinical trial contracts, manufacturing supply, insurance and other obligations also arise in the ordinary course of business. We anticipate the timing of payments under these contracts to range from less than one year to more than three years. Contingencies In April 2009, December 2009 and June 2010, the Italian Tax Authority, or the ITA, issued notices of assessment to CTI - Sede Secondaria, or CTI (Europe), based on the ITA’s audit of CTI (Europe)’s value added tax, or VAT, returns for the years 2003, 2005, 2006 and 2007, or, collectively, the VAT Assessments. The ITA audits concluded that CTI (Europe) did not collect and remit VAT on certain invoices issued to non-Italian clients for services performed by CTI (Europe). The assessments, including interest and penalties, for the years 2003, 2006 and 2007 are €0.6 million , €2.8 million and €0.9 million , respectively. We believe that the services invoiced were non-VAT taxable consultancy services and that the VAT returns are correct as originally filed. We have appealed all the assessments and are defending ourselves against the assessments both on procedural grounds and on the merits of the cases, although we can make no assurances regarding the ultimate outcome of these cases. Following is a summary of the status of the legal proceedings surrounding each respective VAT year return at issue: 2003 VAT Assessment . In June 2013, the Regional Tax Court issued decision no. 119/50/13 in regards to the 2003 VAT Assessment, which accepted the October 2012 appeal of the ITA and reversed a previous decision of the Provincial Tax Court. In January 2014, we appealed such decision to the Italian Supreme Court both on procedural grounds and on the merits of the case. In March 2014 , we paid a deposit in respect of the 2013 VAT matter of €0.4 million (or $0.6 million upon conversion from euros as of the date of payment), following the ITA's request for such payment, which is included in Other assets in our consolidated balance sheets. 2005 VAT Assessment. In January 2018, the Italian Supreme Court issued decision No. 02250/2018 which (i) rejected the April 2013 appeal of the ITA, (ii) confirmed the October 2012 decision of the Regional Tax Court (127/31/2012), which fully accepted the merits of our earlier appeal and confirmed that no penalties could be imposed against us, and (iii) due to the novelty of the arguments at stake, compensated the legal expenses incurred by the parties. The ITA may not use any ordinary means of appeal against the Italian Supreme Court decision, and we have applied for a refund based on the guidance from the ITA. 2006 and 2007 VAT Assessments. In November 2013, the ITA appealed to the Italian Supreme Court an April 2013 decision of the Regional Tax Court (57/35/13), that fully rejected the merits of an earlier ITA appeal, declared that no penalties could be imposed against us and found the ITA liable to pay us approximately €12,000 , as a partial refund of legal expenses we incurred. No hearing dates have been fixed yet for either the 2003 VAT Assessment or consolidated 2006 and 2007 VAT Assessment cases. If the final decision of the Italian Supreme Court is unfavorable to us, or if, in the interim, the ITA were to make a demand for payment and we were to be unsuccessful in suspending collection efforts, we may be requested to pay the ITA an amount up to €4.3 million , or approximately $4.8 million converted using the currency exchange rate as of December 31, 2019 , including interest and penalties for the period lapsed between the date in which the assessments were issued and the date of effective payment. We have not recorded this contingent liability in the financial statements as we do not believe the potential payment to the ITA is probable at this time.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	17. Income Taxes We file income tax returns in the United States and the United Kingdom. A substantial part of our operations takes place in the State of Washington, which does not impose an income tax as that term is defined in ASC 740, Accounting for Income Taxes . As such, our state income tax expense or benefit, if recognized, would be immaterial to our operations. We are not currently under examination by an income tax authority, nor have we been notified that an examination is contemplated. Loss before income taxes is attributable to the following tax jurisdictions (in thousands): Year ended December 31, 2019 2018 United States $ (40,242 ) $ (29,162 ) Foreign 219 (190 ) Net loss before noncontrolling interest and income taxes $ (40,023 ) $ (29,352 ) The reconciliation between the income tax rate and our effective tax rate as of December 31 is as follows: 2019 2018 Federal income tax rate 21 % 21 % Research and development tax credits 14 6 Non-deductible executive compensation (2 ) (1 ) Valuation allowance (31 ) (12 ) Expired tax attribute carryforwards — (17 ) Gain on foreign entity liquidation 1 3 Foreign currency gains and losses 1 2 Unrecognized tax benefits (3 ) — Other (1 ) (2 ) Net effective tax rate — % — % The principal components of our deferred tax assets and liabilities as of December 31 were as follows (in thousands): 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 27,151 $ 18,792 Capitalized research and development 32,907 32,029 Research and development tax credit carryforwards 7,317 3,061 Stock-based compensation 3,109 2,940 Intangible assets 7,519 7,802 Depreciation and amortization 618 549 Lease liability 1,039 — Other deferred tax assets 918 1,806 Total deferred tax assets 80,578 66,979 Less: valuation allowance (79,506 ) (66,698 ) 1,072 281 Deferred tax liabilities: Right-of-use asset (667 ) — Deductions for tax in excess of financial statements (405 ) (281 ) Total deferred tax liabilities (1,072 ) (281 ) Net deferred tax assets $ — $ — As of December 31, 2019 and 2018 , we had U.S. federal net operating loss carryforwards, or the NOL, of approximately $92.0 million and $56.6 million respectively, which are available to reduce future taxable income. The Tax Cuts and Jobs Act enacted in December 2017 altered the carryforward period for federal net operating losses and as a result, all net operating losses generated in 2018 and forward have an indefinite life. Of the net operating losses reported, we have accumulated $48.7 million with an indefinite life as of December 31, 2019 . We have accumulated state tax losses of approximately $12.7 million and $18.0 million as of December 31, 2019 and 2018 , respectively. We also had U.S. federal tax credits of $7.3 million and $3.1 million as of December 31, 2019 and 2018 , respectively, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards began to expire in 2018 and may become subject to annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, or the IRC, of 1986, as amended. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or future tax liabilities. We have undertaken a formal IRC Section 382 study and the attributes disclosed in this footnote reflect the conclusion of that study. However, subsequent ownership changes may further affect the limitation in future years. At December 31, 2019 , the NOL carryforwards in the United Kingdom, which have an indefinite carryforward period, were approximately $40.9 million . Certain of the net operating loss deferred tax assets in the table above, totaling $10.3 million at December 31, 2019 are consolidated in our U.S. GAAP income tax provision due to our 60% ownership in Aequus; however, Aequus is not consolidated for income tax purposes and therefore these net operating losses will not be available to us in our future tax filings. We maintain a full valuation allowance on our net deferred tax assets. The assessment regarding whether a valuation allowance is required considers both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. In making this assessment, significant weight is given to evidence that can be objectively verified. In our valuation, we considered our cumulative loss in recent years and forecasted losses in the near term as significant negative evidence. Based upon a review of the four sources of income identified within ASC 740, we determined that the negative evidence outweighed the positive evidence and that a full valuation allowance on our net deferred tax assets will be maintained. We will continue to assess the realizability of our deferred tax assets going forward and will adjust the valuation allowance as needed. Our valuation allowance increased by $12.8 million during the year ended December 31, 2019 primarily due to increases in capitalized research and development, increases in our tax credit carryforwards and increases in our net operating loss carryforwards. We follow the provisions in ASC 740 and the guidance related to accounting for uncertainty in income taxes. We determine our uncertain tax positions based on a determination of whether and how much of a tax benefit taken by us in our tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. We are subject to U.S. federal and state and U.K. income taxes with varying statutes of limitations. Tax years from 2000 forward remain open to examination due to the carryover of net operating losses or tax credits. Our policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The total balance of unrecognized tax benefits as of December 31 is as follows (in thousands): 2019 2018 Balance at beginning of period $ — $ — Gross increases to tax positions in prior periods 633 — Gross increases to tax positions in current periods 635 — Balance at end of period $ 1,268 $ — As of December 31, 2019 , the total amount of unrecognized tax benefits was $1.3 million , which was recorded as a reduction to the deferred tax asset. We do not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease within the next 12 months. We had no accrued interest or penalties as of December 31, 2019 . As discussed in Note 1. Description of Business and Summary of Significant Accounting Policies - Recently Adopted Accounting Standards, the FASB issued new accounting guidance which modifies ASC 740 - Income Taxes to simplify the accounting for income taxes. We have early adopted this standard on January 1, 2019. Since we have incurred net losses since our inception and maintain a full valuation allowance on our net deferred tax assets, the adoption of this guidance did not have a material impact on our consolidated balance sheets, statements of operations and cash flows or financial statement disclosures.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Rights Offering In March 2020 , we completed a rights offering through the distribution of subscription rights to holders of our common stock and Series O Preferred Stock, or the Rights Offering. Under the Rights Offering and separate purchase commitments by certain of our investors, we sold a total of 15.7 million shares of our common stock and approximately 4,429 shares of Series X Preferred Stock, which are convertible into 44.3 million shares of our common stock, for aggregate gross proceeds of approximately $60.0 million . Total offering costs are estimated to be $0.7 million . As of the date of the filing of this Annual Report on Form 10-K, no shares of Series X Preferred Stock have been converted into common stock. Each share of Series X Preferred Stock has a stated value of $10,000 per share and is convertible into 10,000 shares of our common stock at the option of the holder at any time; subject to certain limitations, including, that the holder will be prohibited from converting Series X Preferred Stock into common stock, if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above a conversion blocker, which is initially set at 9.99% of the total common stock then issued and outstanding immediately following the conversion of such shares of Series X Preferred Stock. In the event of our liquidation, dissolution or winding up, holders of Series X Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock and Series O Preferred Stock holders of Series X Preferred Stock are entitled to receive dividends on shares of Series X Preferred Stock equal (on an as-if-converted-to-common stock basis) to and in the same form as dividends actually paid on the common stock or other junior securities of the Company. Shares of Series X Preferred Stock will generally have no voting rights, except as required by law and except that the consent of a majority of the holders of the outstanding Series X Preferred Stock will be required to amend the terms of the Series X Preferred Stock.

Description of Business and S_2

Description of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Description of Business	CTI BioPharma Corp., together with its wholly-owned subsidiary, also referred to collectively in this Annual Report on Form 10-K as “we,” “us,” “our,” the “Company” and “CTI,” is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products requires approval from, and is subject to, ongoing oversight by the Food and Drug Administration, or the FDA, in the United States, the European Medicines Agency, or the EMA, in the European Union, or the EU, and comparable agencies in other countries. Obtaining approval for a new therapeutic product is never certain, may take many years and may involve expenditure of substantial resources.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of CTI and its wholly-owned subsidiary, CTI Life Sciences Limited, or CTILS, until its dissolution in November 2019. As of December 31, 2019 , we also had an approximately 60% interest in our majority-owned subsidiary, Aequus Biopharma, Inc., or Aequus. The remaining interest in Aequus not held by CTI is reported as noncontrolling interest in the consolidated financial statements. All intercompany transactions and balances are eliminated in consolidation.
Liquidity	We will need to acquire additional funds in order to develop our business and continue the development of pacritinib. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding obtained through the sale of such shares or otherwise may not be sufficient, available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing stockholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly-qualified personnel, be unable to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. The amount of financing we require is dependent on many factors, such as the number of clinical trial sites, the number of patients in the trial, the pace of patient enrollment and other matters that may impact clinical development, including changes to the trial that we may initiate or that may be requested by the FDA or other regulators, and there can be no assurance as to the amount of funding necessary to fund the development of pacritinib to completion. In addition, our ability to comply with covenants under the loan and security agreement with Silicon Valley Bank, or SVB, may be affected by events beyond our control, and we may not be able to meet those covenants. A breach of any of these covenants, including a material adverse change in our business, operations or condition (financial or otherwise) could result in an event of default under the loan and security agreement, which could cause all of the outstanding indebtedness under the facility to become immediately due and payable. The accompanying consolidated financial statements do not include adjustments, if any, that may result from the outcome of this uncertainty. Liquidity The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. Our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. For example, estimates include assumptions used in calculating share-based compensation expense, accruals, the allocation of operating expenses, provision for loss contingencies, the fair value of financial instruments, our tax provision and related valuation allowance, determining the useful lives of fixed assets and potential impairment of long-lived assets. Actual results could differ from those estimates.
Certain Risks, Uncertainties and Concentrations	Certain Risks, Uncertainties and Concentrations We are exposed to risks associated with the translation of euro-denominated financial results and accounts into U.S. dollars for financial reporting purposes. The carrying values of the assets and liabilities, as well as the reported amounts of revenues and expenses are affected by fluctuations in the value of the U.S. dollar as compared to the euro. Certain of our transactions denote monetary amounts in foreign currencies, and consequently, the ultimate financial impact to us from a U.S. dollar perspective is subject to significant uncertainty. We review our foreign currency risk periodically along with hedging options to mitigate such risk. We source our drug products for clinical trials from a concentrated group of third-party contractors. If we are unable to obtain sufficient quantities of source materials, manufacture or distribute our products to customers from existing suppliers and service providers, or obtain the materials or services from other suppliers, manufacturers or distributors, certain research and development and sales activities may be delayed.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: • Level 1—Valuations based on unadjusted quoted prices for identical assets and liabilities in active markets. • Level 2—Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Valuations based on unobservable inputs that are supported by little or no market activity, reflecting our own assumptions. These valuations require significant judgment or estimation. Our cash equivalents and short-term investments are recorded at fair value. As of December 31, 2019 and 2018 , our cash, cash equivalents and short-term investments consisted of cash, money market funds, U.S. government and agency securities and corporate debt securities. We measure the fair value of money market funds based on the closing price reported by a fund sponsor from an actively traded exchange. We value all other securities using broker quotes that utilize observable market inputs. We did not hold cash, cash equivalents and short-term investments categorized as Level 3 assets as of December 31, 2019 and 2018 .
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid instruments with original maturities of three months or less at the time acquired to be cash equivalents.
Receivables from License and Development Services Arrangements	Receivables from License and Development Services Arrangements Our receivables relate to amounts payable or reimbursable to us under the terms of license and development services arrangements with our partners. The receivable balance as of December 31, 2018 related primarily to a milestone receivable from Servier for the attainment of a regulatory milestone in November 2018 as well as a milestone receivable from Teva for the attainment of a worldwide net sales milestone of TRISENOX in December 2018. There were no such receivables as of December 31, 2019 . Receivables are reviewed for collectability whenever circumstances indicate that the carrying amount of the receivable may not be recoverable.
Italian Value Added Tax Receivable	Italian Value Added Tax Receivable We historically carried out research and development activities in Italy and incurred value added tax, or VAT, from Italian suppliers on the acquisition of goods and services in Italy. This VAT should be considered as an Input VAT credit. We treated the majority of our sales made in Italy without output VAT (on the basis that the supplies should be considered outside the scope of Italian VAT). This resulted in the value of input VAT exceeding the value of output VAT, and accordingly we submitted a refund claim for the VAT. The Italian Tax Authority, or the ITA, has challenged the treatment of the sales transactions and claimed that the sales transactions made by us should have been subject to output VAT. Our Italian VAT receivable was approximately $4.4 million and $4.5 million as of December 31, 2019 and 2018 , respectively. Substantially all of our VAT receivable is included in Other assets . As disclosed in Note 16. Commitments and Contingencies , the ITA assessed us for additional VAT payments for services we provided in Italy, which we do not believe we owe. We have not recorded an amount in the financial statements for this contingent liability as we do not believe the potential payment of up to €4.3 million (or approximately $4.8 million converted using the currency exchange rate as of December 31, 2019 ), to the ITA is probable at this time.
Leases	Leases As discussed in Recently Adopted Accounting Standards below, we adopted Accounting Standards Codification, or ASC, Topic 842 - Leases, on January 1, 2019. Under ASC 842, we determine if an arrangement is a lease at inception. We recognize a right-of-use asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as operating or finance at lease commencement, which will affect the pattern and classification of expense recognition in our consolidated statements of operations. Right-of-use assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our leases do not provide a readily determinable implicit rate of return, we use our incremental borrowing rate to derive the present value of lease payments, which is the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. An operating lease right-of-use asset is measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentives received, unamortized initial direct costs and the impairment of the right-of-use asset. A lease may include options to extend or terminate the lease. When it is reasonably certain that we will exercise such an option, it is considered in the lease term. Right-of-use assets are tested for impairment in the same manner as long-lived assets used in operations. Leasehold improvements are capitalized at cost and amortized over the lesser of their expected useful life or the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term as part of Research and development expenses and Selling, general and administrative expenses in our consolidated statements of operations. Right-of-use assets are included in Other assets. The current portion of lease liabilities and the non-current portion of lease liabilities are included in Other current liabilities and Other liabilities , respectively, in our consolidated balance sheets.
Property and Equipment	Property and Equipment Property and equipment are carried at cost, less accumulated depreciation and amortization. Depreciation commences at the time assets are placed in service. We calculate depreciation using the straight-line method over the estimated useful lives of the assets, ranging from three to five years for assets other than leasehold improvements. We amortize leasehold improvements over the lesser of their useful lives of 10 years or the term of the applicable lease.
Impairment of Long-lived Assets	Impairment of Long-lived Assets We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If an impairment is indicated, the asset is written down to its estimated fair value.
Contingencies	Contingencies We record liabilities associated with loss contingencies to the extent that we conclude that the occurrence of the contingency is probable and that the amount of the related loss is reasonably estimable. We record income from gain contingencies only upon the realization of assets resulting from the favorable outcome of the contingent event. See Note 10. Collaboration, Licensing and Milestone Agreements and Note 16. Commitments and Contingencies for further information regarding our current contingencies.
Revenue Recognition	Revenue Recognition ASC 606 - Revenue from Contracts with Customers applies to all contracts with customers, except for contracts that are within the scope of other authoritative literature. Under ASC 606, we recognize revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy a performance obligation. We apply the five-step model to arrangements that meet the definition of a contract under ASC 606 including when it is probable that we will collect the consideration we are entitled to in exchange for goods or services we transfer to the customer. At contract inception, we assess the goods or services promised within each contract and determine those that are performance obligations, and assesses whether each promised good or service is distinct. We recognize revenue for the amount of the transaction price that is allocated to the respective performance obligation as the performance obligation is satisfied. License and Development Services Arrangements We recognize license and contract revenue under license and development services arrangements that are within the scope of ASC 606. The terms of these agreements may contain multiple performance obligations, which may include licenses and research and development activities. We evaluate these agreements under ASC 606 to determine distinct performance obligations. Prior to recognizing revenue, we make estimates of the transaction price, including any variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that there will not be a significant reversal in the amount of cumulative revenue recognized and when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include nonrefundable upfront license fees, payments for research and development activities, reimbursement of certain third-party costs, payments based upon the achievement of specified milestones, and royalty payments based on product sales derived from the collaboration. If there are multiple, distinct performance obligations, we allocate the transaction price to each distinct performance obligation based on its relative standalone selling price. Revenue is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure in accordance with ASC-340-40, Other Assets and Deferred Costs: Contracts with Customers .
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development . Research and development expenses include related salaries and benefits, clinical trial and related manufacturing costs, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaboration research and development and include activities such as product registries and investigator-sponsored trials. In instances where we enter into agreements with third parties for research and development activities, we may prepay fees for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Other types of arrangements with third parties may be fixed fee or fee for service, and may include monthly payments or payments upon completion of milestones or receipt of deliverables. We expense upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.
Foreign Currency Translation and Transaction Gains and Losses	Foreign Currency Translation and Transaction Gains and Losses We record foreign currency translation adjustments and transaction gains and losses in accordance with ASC 830, Foreign Currency Matters. For operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss, but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of stockholders’ equity, except for intercompany transactions that are of a short-term nature with entities that are consolidated, combined or accounted for by the equity method in our consolidated financial statements. We have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of operations related to the recurring measurement and settlement of such transactions. During the year ended December 31, 2019 , in connection with the dissolution of CTILS, a gain in the amount of $1.3 million was released from the cumulative foreign currency translation adjustment account and recorded in Other non-operating income in the consolidated statement of operations in accordance with ASC 830, Foreign Currency Matters. See Note 9. Other Comprehensive Loss for additional details.
Income Taxes	Income Taxes We record a tax provision for the anticipated tax consequences of our results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates in effect for the years in which those tax assets and liabilities are expected to be realized or settled. We provide a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.
Net Loss per Share	Net Loss per Share Basic net loss per common share is calculated based on the net loss attributable to common stockholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per common share excludes the potential conversion of all dilutive convertible securities, such as convertible preferred stock, using the if-converted method, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, using the treasury stock method, as their inclusion would have an anti-dilutive effect.
Recent Accounting Standards	Recently Adopted Accounting Standards In February 2016, the FASB issued ASC 842 - Leases , which requires lessees to recognize virtually all of their leases (other than leases that meet the definition of a short-term lease) on the balance sheet. On January 1, 2019, we adopted ASC 842 using the modified retrospective approach with a cumulative-effect adjustment as of January 1, 2019 in accordance with ASU No. 2018-11, Leases (Topic 842) - Targeted Improvements . Prior period amounts are not adjusted and continue to be reported under previous lease guidance, ASC 840 - Leases . We have performed an evaluation of our contracts with customers and suppliers in accordance with ASC 842 and have determined that the agreements for our office space, parking and office equipment contained a lease. All identified leases are classified as operating leases. We had no finance or capital leases as of and for the years ended December 31, 2019 and 2018 . We also elected a package of practical expedients permitted under the transition guidance within the new standard. The impact of the adoption of ASC 842 on our consolidated balance sheet as of January 1, 2019 was as follows (in thousands): December 31, 2018 Adjustments due to adoption of ASC 842 January 1, 2019 Right-of-use assets $ — $ 4,208 $ 4,208 Lease liabilities, current $ — $ 1,687 $ 1,687 Lease liabilities, non-current $ — $ 4,946 $ 4,946 Deferred rent, current $ 893 $ (893 ) $ — Deferred rent, non-current $ 2,157 $ (2,157 ) $ — Accumulated deficit $ (2,224,746 ) $ 1,196 $ (2,223,550 ) The adoption of the standard did not materially impact our consolidated statements of operations or consolidated statements of cash flows. See Note 5. Leases for further details about our leases. In June 2018, the FASB issued new accounting guidance which simplifies the accounting for share-based payments granted to nonemployees for goods and services by aligning it with the accounting for share-based payments to employees, with certain exceptions. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We adopted this guidance on January 1, 2019. The adoption of this accounting guidance did not have a material impact on our consolidated financial statements. In December 2019, the FASB issued new accounting guidance which modifies ASC 740 - Income Taxes to simplify the accounting for income taxes. These modifications include, among other things, elimination of certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption is permitted. We early adopted this guidance on January 1, 2019. The adoption of this accounting guidance did not have a material impact on our consolidated financial statements. See Note 17. Income Taxes for further details. Recently Issued Accounting Standards In June 2016, the FASB issued new accounting guidance which amends the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. We do not expect the adoption of this accounting guidance to have a material impact on our consolidated financial statements. In August 2018, the FASB issued new accounting guidance which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We do not expect the adoption of this accounting guidance to have a material impact on our consolidated financial statements. Although there were several other new accounting pronouncements issued or proposed by the FASB, we do not believe any of these have had or will have material impact on our consolidated financial statements.
Reclassifications	Reclassifications Certain prior year items have been reclassified to conform to current year presentation

Description of Business and S_3

Description of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Cash and Cash Equivalents, Measured at Fair Value on a Recurring Basis	The following table summarizes, by major security type, our cash, cash equivalents and short-term investments that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands): December 31, 2019 December 31, 2018 Cost or Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Total Estimated Fair Value Total Estimated Fair Value Cash $ 188 $ — $ — $ 188 $ 919 Level 1 securities: Money market funds 28,957 — — 28,957 20,525 Level 2 securities: U.S. government and agency securities 2,522 — — 2,522 15,213 Corporate debt securities 1,999 — — 1,999 30,381 Total cash, cash equivalents and short-term investments $ 33,666 $ — $ — $ 33,666 $ 67,038
Impact of Adoption of ASC 842 on Balance Sheet	The impact of the adoption of ASC 842 on our consolidated balance sheet as of January 1, 2019 was as follows (in thousands): December 31, 2018 Adjustments due to adoption of ASC 842 January 1, 2019 Right-of-use assets $ — $ 4,208 $ 4,208 Lease liabilities, current $ — $ 1,687 $ 1,687 Lease liabilities, non-current $ — $ 4,946 $ 4,946 Deferred rent, current $ 893 $ (893 ) $ — Deferred rent, non-current $ 2,157 $ (2,157 ) $ — Accumulated deficit $ (2,224,746 ) $ 1,196 $ (2,223,550 )

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment are composed of the following as of December 31, 2019 and 2018 (in thousands): 2019 2018 Furniture and office equipment $ 2,872 $ 4,445 Leasehold improvements 5,140 5,168 Lab equipment — 63 8,012 9,676 Less: accumulated depreciation and amortization (6,777 ) (7,883 ) Property and equipment, net $ 1,235 $ 1,793

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets consisted of the following as of December 31, 2019 and 2018 (in thousands): 2019 2018 Right-of-use assets $ 3,379 $ — Italian VAT receivables 4,390 4,480 Italian VAT deposit 483 493 Clinical trial deposits 720 — Refundable security deposit 194 194 Other 299 380 Other assets $ 9,465 $ 5,547

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following as of December 31, 2019 and 2018 (in thousands): 2019 2018 Clinical trial expenses $ 7,920 $ 6,573 Employee compensation and related expenses 2,851 4,216 Restructuring expenses — 660 Manufacturing expenses 228 458 Other 607 945 Total accrued expenses $ 11,606 $ 12,852

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Components of Lease Expenses and Supplemental Information	Supplemental information relating to our operating leases is as follows (in thousands): December 31, 2019 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities $ 2,391 Weighted-average remaining lease term of operating leases (years) 2.31 Weighted-average discount rate of operating leases 12.4 % The components of lease expense, which were included in our consolidated statements of operations, were as follows (in thousands): Year Ended December 31, 2019 2018 Operating lease expense $ 1,696 $ 1,384 Variable lease expense 178 195 Sublease income (1,247 ) (1,247 ) Total lease expense, net $ 627 $ 332
Balance Sheet Classification of Operating Lease Components	The balance sheet classification of operating lease right-of-use assets and operating lease liabilities were as follows (in thousands): December 31, 2019 Right-of-use assets (included in Other assets ) $ 3,379 Lease liabilities, current (included in Other current liabilities ) $ 1,953 Lease liabilities, non-current (included in Other liabilities ) 2,993 Total lease liabilities $ 4,946
Schedule of Future Minimum Operating Lease Payments and Receivables	As of December 31, 2019 , the maturities of operating lease liabilities were as follows (in thousands): Operating Sublease Lease Payments Rental Receipts Net 2020 $ 2,443 $ (1,410 ) $ 1,033 2021 2,438 (1,454 ) 984 2022 820 (499 ) 321 Thereafter — — — Total payments 5,701 $ (3,363 ) $ 2,338 Less imputed interest (755 ) Total lease liabilities $ 4,946
Schedule of Future Minimum Operating Lease Payments and Receivables	As of December 31, 2019 , the maturities of operating lease liabilities were as follows (in thousands): Operating Sublease Lease Payments Rental Receipts Net 2020 $ 2,443 $ (1,410 ) $ 1,033 2021 2,438 (1,454 ) 984 2022 820 (499 ) 321 Thereafter — — — Total payments 5,701 $ (3,363 ) $ 2,338 Less imputed interest (755 ) Total lease liabilities $ 4,946

Other Liabilities (Tables)

Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Components of Other Liabilities	Other liabilities consisted of the following as of December 31, 2019 and 2018 (in thousands): 2019 2018 Lease liabilities, non-current $ 2,993 $ — Deferred rent, non-current — 2,157 Other long-term obligations 2,414 2,414 Total other liabilities $ 5,407 $ 4,571

Long-term Debt (Tables)

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Principal and Interest Payments of Debt	As of December 31, 2019 , the scheduled principal and interest payments (based on the interest rate of 7.25 percent as of December 31, 2019 ) as well as the back-end fee described above are as follows: Principal Interest Back-end fee Total 2020 $ 5,333 $ 573 $ — $ 5,906 2021 4,889 180 1,440 6,509 Thereafter — — — — Total scheduled payments $ 10,222 $ 753 $ 1,440 $ 12,415 Less: debt discount and issuance costs $ (955 ) Less: current portion of long-term debt $ (4,812 ) Long-term debt $ 4,455

Equity Transactions (Tables)

Equity Transactions (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Summary of Common Stock Reserved for Issuance	As of December 31, 2019 , we had 131.5 million authorized shares of common stock, of which 58.0 million shares were issued and outstanding, and 21.4 million shares were reserved for future issuances as follows (in thousands): Equity incentive plans 11,211 Option agreement with Adam R. Craig 1,120 Common stock purchase warrants 514 Series O convertible preferred stock 8,383 Employee stock purchase plan 176 Total common stock reserved 21,404

Other Comprehensive Loss (Table

Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of Total Accumulated Other Comprehensive Loss	Total accumulated other comprehensive loss consisted of the following (in thousands): Net Unrealized (Loss) Gain on Available-For-Sale Securities Foreign Currency Translation Adjustments (1) Unrealized Foreign Exchange Loss on Intercompany Balance (1) Accumulated Other Comprehensive Loss December 31, 2018 $ (14 ) $ (9,672 ) $ (957 ) $ (10,643 ) Current period other comprehensive income (loss) 16 (2,323 ) 957 (1,350 ) December 31, 2019 $ 2 $ (11,995 ) $ — $ (11,993 ) (1) In accordance with ASC 830, Foreign Currency Matters , the current period change includes a release of cumulative translation adjustment in the amount of $1.3 million upon dissolution of CTILS, our foreign subsidiary, which was recognized in Other non-operating income in the consolidated statement of operations for the year ended December 31, 2019 .

Restructuring Activities (Table

Restructuring Activities (Tables)	12 Months Ended
	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Summary of the Accrual Balance and Utilization of Restructuring	The following table summarizes the accrual balance and utilization for the year ended December 31, 2019 (in thousands): Employee separation costs Restructuring accruals - December 31, 2018 $ 660 Restructuring expenses 794 Cash payments (1,454 ) Restructuring accruals - December 31, 2019 $ —

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Expense by Types of Awards	During the years ended December 31, 2019 and 2018 , we recognized share-based compensation expense which consisted of the following types of awards (in thousands): 2019 2018 Restricted stock — 102 Options 5,166 6,267 Total share-based compensation expense $ 5,166 $ 6,369
Summary of Share-Based Compensation Expense	The following table summarizes share-based compensation expense for the years ended December 31, 2019 and 2018 , which was allocated as follows (in thousands): 2019 2018 Research and development $ 506 $ 1,950 Selling, general and administrative 4,660 4,419 Total share-based compensation expense $ 5,166 $ 6,369
Schedule of Black Scholes Stock Option Pricing Model Weighted Average Assumptions	Fair value for stock options was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions: Year Ended December 31, 2019 2018 Risk-free interest rate 2.3 % 2.9 % Expected dividend yield None None Expected life (in years) 4.4 5.4 Volatility 89 % 82 %
Stock Option Activity for All Stock Plans	The following table summarizes stock option activity for all of our stock option plans: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Thousands) Outstanding at December 31, 2018 (2,597,000 exercisable) 7,219,000 $ 4.08 Granted 5,307,000 $ 0.91 Exercised — $ — Forfeited (1,115,000 ) $ 2.16 Cancelled and expired (457,000 ) $ 8.35 Outstanding at December 31, 2019 (4,047,000 exercisable) 10,954,000 $ 2.56 8.3 $ 3,504 Vested or expected to vest at December 31, 2019 10,510,000 $ 2.61 8.3 $ 3,252 Exercisable at December 31, 2019 4,047,000 $ 4.39 7.2 $ 6
Summary of Status of Nonvested Restricted Stock Awards and Units	A summary of the status of nonvested restricted stock awards as of December 31, 2019 and 2018 and changes during the periods then ended, is presented below: Nonvested Shares Weighted Average Grant-Date Fair Value Per Share Nonvested at December 31, 2017 63,000 $ 15.93 Issued — $ — Vested (35,000 ) $ 12.00 Forfeited (15,000 ) $ 16.12 Nonvested at December 31, 2018 13,000 $ 26.23 Issued — $ — Vested — $ — Forfeited (8,000 ) $ 19.12 Nonvested at December 31, 2019 5,000 $ 38.90

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Shares	The computation of net loss per share is as follows (in thousands, except per share amounts): Year Ended December 31, 2019 2018 Net loss attributable to common stockholders $ (40,020 ) $ (29,400 ) Basic and diluted: Weighted average shares outstanding 57,980 56,106 Less: weighted average restricted shares outstanding (6 ) (33 ) Shares used in calculation of basic and diluted net loss per common share 57,974 56,073 Net loss per common share: Basic and diluted $ (0.69 ) $ (0.52 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Loss Before Income Taxes	Loss before income taxes is attributable to the following tax jurisdictions (in thousands): Year ended December 31, 2019 2018 United States $ (40,242 ) $ (29,162 ) Foreign 219 (190 ) Net loss before noncontrolling interest and income taxes $ (40,023 ) $ (29,352 )
Reconciliation Between Effective Tax Rate and Income Tax Rate	The reconciliation between the income tax rate and our effective tax rate as of December 31 is as follows: 2019 2018 Federal income tax rate 21 % 21 % Research and development tax credits 14 6 Non-deductible executive compensation (2 ) (1 ) Valuation allowance (31 ) (12 ) Expired tax attribute carryforwards — (17 ) Gain on foreign entity liquidation 1 3 Foreign currency gains and losses 1 2 Unrecognized tax benefits (3 ) — Other (1 ) (2 ) Net effective tax rate — % — %
Significant Components of Deferred Tax Assets and Liabilities	The principal components of our deferred tax assets and liabilities as of December 31 were as follows (in thousands): 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 27,151 $ 18,792 Capitalized research and development 32,907 32,029 Research and development tax credit carryforwards 7,317 3,061 Stock-based compensation 3,109 2,940 Intangible assets 7,519 7,802 Depreciation and amortization 618 549 Lease liability 1,039 — Other deferred tax assets 918 1,806 Total deferred tax assets 80,578 66,979 Less: valuation allowance (79,506 ) (66,698 ) 1,072 281 Deferred tax liabilities: Right-of-use asset (667 ) — Deductions for tax in excess of financial statements (405 ) (281 ) Total deferred tax liabilities (1,072 ) (281 ) Net deferred tax assets $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward	The total balance of unrecognized tax benefits as of December 31 is as follows (in thousands): 2019 2018 Balance at beginning of period $ — $ — Gross increases to tax positions in prior periods 633 — Gross increases to tax positions in current periods 635 — Balance at end of period $ 1,268 $ —

Description of Business and S_4

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, € in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2019USD ($)$ / shares	Jan. 01, 2019USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2018USD ($)$ / shares	Jan. 24, 2018$ / shares	Jan. 23, 2018$ / shares
Description Of Business And Significant Accounting Policies [Line Items]
Preferred stock par value (in USD per share) | $ / shares									$ 0.001	$ 0
Common stock par value (in USD per share) | $ / shares					$ 0.001			$ 0.001	$ 0.001	$ 0
Accumulated deficit					$ (2,263,563,000)	$ (2,223,550,000)		$ (2,224,746,000)
Available cash and cash equivalents					33,700,000
Allowance for doubtful accounts from collaborative arrangements					0			0
Italian VAT receivables					4,400,000			4,500,000
VAT potential payment				€ 4.3	4,800,000
Foreign currency translation		$ 957,000	$ (1,513,000)
Finance lease					$ 0
Capital lease								0
Leasehold Improvements
Description Of Business And Significant Accounting Policies [Line Items]
Property and equipment useful life		10 years
Minimum | Assets Other Than Leasehold Improvements
Description Of Business And Significant Accounting Policies [Line Items]
Property and equipment useful life		3 years
Maximum | Assets Other Than Leasehold Improvements
Description Of Business And Significant Accounting Policies [Line Items]
Property and equipment useful life		5 years
CTI Life Sciences Limited
Description Of Business And Significant Accounting Policies [Line Items]
Foreign currency translation		$ 1,300,000	$ (1,500,000)
Intercompany foreign currency balance receivable							€ 28.7	$ 32,800,000
Aequus Biopharma, Inc
Description Of Business And Significant Accounting Policies [Line Items]
Interest in majority-owned subsidiary				59.70%	59.70%
Aequus Biopharma, Inc | Affiliated Entity
Description Of Business And Significant Accounting Policies [Line Items]
Interest in majority-owned subsidiary				60.00%	60.00%
Rights Offering | Subsequent Event
Description Of Business And Significant Accounting Policies [Line Items]
Proceeds from sale of stock	$ 59,300,000

Description of Business and S_5

Description of Business and Summary of Significant Accounting Policies - Cash and Cash Equivalents and Short-term Investments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Level 2 securities:
Gross Unrealized Gains	$ 0
Gross Unrealized Losses	0
Cost or Amortized Cost
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash	188
Level 2 securities:
Total	33,666
Total Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash	188	$ 919
Level 2 securities:
Total	33,666	67,038
Money market funds | Level 1 | Cost or Amortized Cost
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Money market funds	28,957
Money market funds | Level 1 | Total Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Money market funds	28,957	20,525
U.S. government and agency securities | Level 2
Level 2 securities:
Gross Unrealized Gains	0
Gross Unrealized Losses	0
U.S. government and agency securities | Level 2 | Cost or Amortized Cost
Level 2 securities:
Cost or Amortized Cost	2,522
U.S. government and agency securities | Level 2 | Total Estimated Fair Value
Level 2 securities:
Total Estimated Fair Value	2,522	15,213
Corporate debt securities | Level 2
Level 2 securities:
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Corporate debt securities | Level 2 | Cost or Amortized Cost
Level 2 securities:
Cost or Amortized Cost	1,999
Corporate debt securities | Level 2 | Total Estimated Fair Value
Level 2 securities:
Total Estimated Fair Value	$ 1,999	$ 30,381

Description of Business and S_6

Description of Business and Summary of Significant Accounting Policies - Impact of Adoption of ASC 842 (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Right-of-use assets	$ 3,379	$ 4,208
Lease liabilities, current	1,953	1,687
Lease liabilities, non-current	2,993	4,946
Deferred rent, current			$ 893
Deferred rent, non-current			2,157
Accumulated deficit	$ (2,263,563)	(2,223,550)	$ (2,224,746)
Adjustments due to adoption of ASC 842
Lessee, Lease, Description [Line Items]
Right-of-use assets		4,208
Lease liabilities, current		1,687
Lease liabilities, non-current		4,946
Deferred rent, current		(893)
Deferred rent, non-current		(2,157)
Accumulated deficit		$ 1,196

Property and Equipment (Detail)

Property and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property and Equipment, Gross	$ 8,012	$ 9,676
Less: accumulated depreciation and amortization	(6,777)	(7,883)
Property and equipment, net	1,235	1,793
Depreciation expense	546	593
Furniture and office equipment
Property Plant And Equipment [Line Items]
Property and Equipment, Gross	2,872	4,445
Leasehold improvements
Property Plant And Equipment [Line Items]
Property and Equipment, Gross	5,140	5,168
Lab equipment
Property Plant And Equipment [Line Items]
Property and Equipment, Gross	$ 0	$ 63

Other Assets (Details)

Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Right-of-use assets	$ 3,379	$ 4,208
Italian VAT receivables	4,390		$ 4,480
Italian VAT deposit	483		493
Clinical trial deposits	720		0
Refundable security deposit	194		194
Other	299		380
Other assets	$ 9,465		$ 5,547

Accrued Expenses (Detail)

Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Clinical trial expenses	$ 7,920	$ 6,573
Employee compensation and related expenses	2,851	4,216
Restructuring expenses	0	660
Manufacturing expenses	228	458
Other	607	945
Total accrued expenses	$ 11,606	$ 12,852

Leases - Additional Information

Leases - Additional Information (Detail) ft² in Thousands	1 Months Ended
	Jan. 31, 2012USD ($)ft²Option	Dec. 31, 2017USD ($)ft²
Leases [Abstract]
Area of office spaces | ft²	66	44
Lease term	120 months
Number of options to extend the term | Option	2
Extend option term	5 years
Option to early terminate, period	5 years
Allowance for tenant improvements	$ 3,900,000
Sublease payments receivable within five months		$ 0

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Operating lease expense	$ 1,696	$ 1,384
Variable lease expense	178	195
Sublease income	(1,247)	(1,247)
Total lease expense, net	$ 627	$ 332

Leases - Balance Sheet Classifi

Leases - Balance Sheet Classification of Operating Lease Components (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019
Leases [Abstract]
Right-of-use assets (included in Other assets)	$ 3,379	$ 4,208
Lease liabilities, current (included in Other current liabilities)	1,953	1,687
Lease liabilities, non-current (included in Other liabilities)	2,993	$ 4,946
Total lease liabilities	$ 4,946

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Operating Leases Future Minimum Payments
Operating Lease Payments, 2020	$ 2,443
Operating Lease Payments, 2021	2,438
Operating Lease Payments, 2022	820
Operating Lease Payments, Thereafter	0
Operating Lease Payments, Total payments	5,701
Less imputed interest	(755)
Total lease liabilities	4,946
Sublease Rentals Future Payments Receivable
Sublease Rental Receipts, 2020	(1,410)
Sublease Rental Receipts, 2021	(1,454)
Sublease Rental Receipts, 2022	(499)
Sublease Rental Receipts, Thereafter	0
Sublease Rental Receipts, Total payments	3,363
Net, 2020	1,033
Net, 2021	984
Net, 2022	321
Net, Thereafter	0
Net, Total payments	$ 2,338

Leases - Supplemental Informati

Leases - Supplemental Information Relating to Operating Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 2,391
Weighted-average remaining lease term of operating leases (years)	2 years 3 months 22 days
Weighted-average discount rate of operating leases	12.40%

Other Liabilities (Detail)

Other Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Nov. 30, 2017
Other Liabilities Disclosure [Abstract]
Lease liabilities, non-current	$ 2,993	$ 4,946
Deferred rent, non-current			$ 2,157
Other long-term obligations	2,414		2,414
Total other liabilities	5,407		4,571
Silicon Valley Bank | Secured Debt | Loan and Security Agreement
Debt Instrument [Line Items]
Fee amount on term loan	$ 1,400		$ 1,400	$ 1,400

Long-term Debt - Additional Inf

Long-term Debt - Additional Information (Detail) - Secured Debt - Loan and Security Agreement - Silicon Valley Bank - USD ($)	1 Months Ended
	Nov. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Jul. 31, 2018
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 18,000,000
Proceeds from line of credit	$ 16,000,000
Remaining borrowing capacity				$ 2,000,000
Repayment term	36 months
Interest only period	12 months
Prime interest rate	6.75%
Fee payable when loan is paid or payable in full	9.00%
Fee amount on term loan	$ 1,400,000	$ 1,400,000	$ 1,400,000
Fair value of warrants	500,000
Debt instrument unamortized discount	1,900,000	900,000
Debt issuance costs	$ 100,000
Debt instrument unamortized issuance cost		100,000
Outstanding principal balance		$ 10,200,000
Interest rate		7.25%
Participation Arrangement
Debt Instrument [Line Items]
Number of warrants issued (in shares)	190,140
Warrant exercise price (in USD per share)	$ 2.84
Prime Rate
Debt Instrument [Line Items]
Interest rate above prime rate	2.50%

Long-term Debt - Principal and

Long-term Debt - Principal and Interest Payments of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Principal
Scheduled payments, Principal, 2020	$ 5,333
Scheduled payments, Principal, 2021	4,889
Scheduled payments, Principal, Thereafter	0
Total scheduled payments, Principal	10,222
Less: debt discount and issuance costs	(955)
Less: current portion of long-term debt	(4,812)	$ (4,812)
Long-term debt	4,455
Interest
Scheduled payments, Interest, 2020	573
Scheduled payments, Interest, 2021	180
Scheduled payments, Interest, Thereafter	0
Total scheduled payments, Interest	753
Back-end fee
Scheduled payments, Back-end fee, 2020	0
Scheduled payments, Back-end fee, 2021	1,440
Scheduled payments, Back-end fee, Thereafter	0
Total scheduled payments, Back-end fee	1,440
Total scheduled payments, 2020	5,906
Total scheduled payments, 2021	6,509
Total scheduled payments, Thereafter	0
Total scheduled payments	$ 12,415

Equity Transactions - Preferred

Equity Transactions - Preferred and Common Stock Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Nov. 30, 2019	Feb. 28, 2018	Dec. 31, 2019	Dec. 31, 2018	May 31, 2019	Apr. 30, 2019	May 31, 2018	Apr. 30, 2018	Jan. 24, 2018	Jan. 23, 2018
Class of Stock [Line Items]
Dividends and deemed dividends on preferred stock			$ 0	$ 80
Preferred stock stated value (in USD per share)									$ 0.001	$ 0
Proceeds from common stock offering			0	64,170
Stock issuance costs			$ 275	$ 268
Common stock authorized (in shares)			131,500,000	101,500,000	131,500,000	101,500,000	101,500,000	81,500,000
Common stock issued (in shares)			57,979,725	57,986,075
Common stock outstanding (in shares)			57,979,725	57,986,075
Shares of common stock reserved for future issuance (in shares)			21,404,000
Series O convertible preferred stock
Class of Stock [Line Items]
Preferred stock outstanding (in shares)			12,575	12,575
Preferred stock stated value (in USD per share)			$ 0.001	$ 0.001
Shares of common stock reserved for future issuance (in shares)			8,383,000
Common Stock
Class of Stock [Line Items]
Number of shares issued in conversion (in shares)				(8,000,000)
Stock Issued (in shares)		23,000,000		23,000,000
Stock issued, purchase price (in USD per share)		$ 3
Proceeds from common stock offering		$ 69,000
Stock issuance costs		$ 4,800
BVF Partners, L.P. | Series N Preferred Stock
Class of Stock [Line Items]
Number of shares converted (in shares)		575
BVF Partners, L.P. | Series O convertible preferred stock
Class of Stock [Line Items]
Number of shares issued in conversion (in shares)		12,575
Dividends and deemed dividends on preferred stock				$ 100
Preferred stock outstanding (in shares)			12,575
Conversion price (in USD per share)		$ 3
Preferred stock stated value (in USD per share)			$ 2,000
BVF Partners, L.P. | Common Stock
Class of Stock [Line Items]
Number of shares converted (in shares)		8,000,000
Stock Issued (in shares)		6,300,000
Jefferies | Common Stock
Class of Stock [Line Items]
Stock Issued (in shares)			0
Expected proceeds from common stock offering, net of issuance costs	$ 15,000
Percent of gross proceeds, underwriter commission	3.00%
Write-off of deferred financing costs			$ 200

Equity Transactions - Summary o

Equity Transactions - Summary of Common Stock Reserved for Issuance (Detail) shares in Thousands	Dec. 31, 2019shares
Class of Stock [Line Items]
Total common stock reserved (in shares)	21,404
Series O convertible preferred stock
Class of Stock [Line Items]
Total common stock reserved (in shares)	8,383
Common stock purchase warrants
Class of Stock [Line Items]
Total common stock reserved (in shares)	514
Options | Chief Executive Officer
Class of Stock [Line Items]
Total common stock reserved (in shares)	1,120
Equity incentive plans
Class of Stock [Line Items]
Total common stock reserved (in shares)	11,211
Employee stock purchase plan
Class of Stock [Line Items]
Total common stock reserved (in shares)	176

Equity Transactions - Warrant I

Equity Transactions - Warrant Information (Detail) - Common stock purchase warrants	Dec. 31, 2019$ / sharesshares
Vendor
Class Of Warrant Or Right [Line Items]
Number of warrants issued (in shares)	294,117
Warrant exercise price (in USD per share) | $ / shares	$ 1.7
Third Amendment
Class Of Warrant Or Right [Line Items]
Number of warrants issued (in shares)	29,239
Warrant exercise price (in USD per share) | $ / shares	$ 17.1
Loan and Security Agreement
Class Of Warrant Or Right [Line Items]
Number of warrants issued (in shares)	190,140
Warrant exercise price (in USD per share) | $ / shares	$ 2.84
Warrants outstanding (in shares)	169,014

Other Comprehensive Loss (Detai

Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Changes in AOCI [Roll Forward]
Beginning Balance	$ 52,939	$ 16,090
Current period other comprehensive income (loss)	(1,350)	(4,371)
Ending Balance	17,930	52,939
Accumulated Other Comprehensive Loss
Changes in AOCI [Roll Forward]
Beginning Balance	(10,643)	(6,272)
Current period other comprehensive income (loss)	(1,350)	(4,371)
Ending Balance	(11,993)	(10,643)
Net Unrealized (Loss) Gain on Available-For-Sale Securities
Changes in AOCI [Roll Forward]
Beginning Balance	(14)
Current period other comprehensive income (loss)	16
Ending Balance	2	(14)
Foreign Currency Translation Adjustments
Changes in AOCI [Roll Forward]
Beginning Balance	(9,672)
Current period other comprehensive income (loss)	(2,323)
Ending Balance	(11,995)	(9,672)
Cumulative translation adjustment	1,300
Unrealized Foreign Exchange Loss on Intercompany Balance
Changes in AOCI [Roll Forward]
Beginning Balance	(957)
Current period other comprehensive income (loss)	957
Ending Balance	$ 0	$ (957)

Collaboration, Licensing and _2

Collaboration, Licensing and Milestone Agreements - Additional Information (Detail) € in Thousands	1 Months Ended		12 Months Ended			24 Months Ended
	Jan. 31, 2014USD ($)	Mar. 31, 2000	Dec. 31, 2019USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2018USD ($)	Dec. 31, 2019EUR (€)	Aug. 31, 2019EUR (€)	Oct. 31, 2016USD ($)	May 31, 2012USD ($)	Jun. 30, 2005USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and contract revenues			$ 3,345,000		$ 26,290,000
University of Vermont | PIXUVRI
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Period from first commercial sale		10 years
Termination And Transfer Agreement | Servier
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and contract revenues			2,200,000
Receivable required upon counterparty entering asset purchase agreement | €							€ 2,000
Termination And Transfer Agreement | Servier | License and Service
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and contract revenues			600,000	€ 65		€ 620
Collaborative Arrangement | Cephalon, Inc | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingency milestone payment to be received										$ 100,000,000
Milestone payments received			$ 60,000,000
Collaborative Arrangement | Novartis | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingency milestone payment to be made	$ 16,600,000
Percentage of royalty payable to net sales	10.00%
Asset Return and Termination Agreement | Baxalata | Borrowing Associated With License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingency milestone payment to be made								$ 10,300,000
S_BIO Asset Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingency milestone payment to be made									$ 132,500,000
Milestone payments through the issuance of stock									50.00%
FDA Approval | Collaborative Arrangement | Cephalon, Inc | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized					10,000,000
Worldwide Net Sales | Collaborative Arrangement | Cephalon, Inc | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized					$ 10,000,000

Restructuring Activities (Detai

Restructuring Activities (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2018USD ($)position	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Restructuring and Related Activities [Abstract]
Number of positions impacted | position	21
Restructuring expense expected to incur		$ 1,500
Restructuring expense incurred		800
Restructuring Reserve [Roll Forward]
Restructuring expenses		794	$ 660
Employee separation costs
Restructuring Reserve [Roll Forward]
Beginning balance		660
Restructuring expenses		794
Cash payments		(1,454)
Ending balance	$ 660	$ 0	$ 660

Share-Based Compensation - Expe

Share-Based Compensation - Expense by Types of Awards (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 5,166	$ 6,369
Restricted stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	0	102
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 5,166	$ 6,267

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 5,166	$ 6,369
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	506	1,950
Selling, general and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 4,660	$ 4,419

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail)	1 Months Ended		12 Months Ended
	May 31, 2017	Mar. 31, 2017installment$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2015shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense | $			$ 5,166,000	$ 6,369,000
Unrecognized compensation cost | $			$ 4,700,000
Recognition period			1 year 8 months 23 days
Tax benefits attributed to share-based compensation expense | $			$ 0	$ 0
Shares of common stock reserved for future issuance (in shares)			21,404,000
2007 Equity Incentive Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance (in shares)			13,600,000
Shares available for future grants (in shares)			1,000,000
Employee stock purchase plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance (in shares)			176,000
Options | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance (in shares)			1,120,000
Options expiration period		10 years
Options granted in period (in shares)		1,200,000
Exercise price of options granted (in USD per share) | $ / shares		$ 4.24
Number semi-annual vesting installments | installment		6
Vesting period		3 years
Options | Chief Executive Officer | Stock Option Plan, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted in period (in shares)		80,000
Employee stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance (in shares)					200,000
Employee stock | Employee stock purchase plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance (in shares)			200,000
Shares authorized for issuance (in shares)			200,000
Shares issued in period (in shares)			2,000	5,000
Vested Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Repurchased shares of common stock | $			$ 0	$ 21,000
Repurchased shares of common stock (in shares)			0	5,800
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense | $			$ 5,166,000	$ 6,267,000
Weighted average exercise price of options exercisable (in USD per share) | $ / shares			$ 4.39	$ 5.49
Weighted average fair value of options granted (in USD per share) | $ / shares			$ 0.60	$ 2.09
Options vested or expected to vest (in shares)			10,510,000
Weighted average exercise price, vested or expected to vest (in USD per share) | $ / shares			$ 2.61
Exercise price of options granted (in USD per share) | $ / shares			$ 0.91
Options | 2007 Equity Incentive Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options expiration period	10 years
Performance-based options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vested or expected to vest (in shares)			4,000
Weighted average exercise price, vested or expected to vest (in USD per share) | $ / shares			$ 22.35
Restricted stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense | $			$ 0	$ 102,000
Shares issued in period (in shares)			0	0
Restricted shares, cancelled (in shares)			8,000	15,000
Total fair value of vested restricted stock awards | $			$ 0	$ 100,000

Share-Based Compensation - Weig

Share-Based Compensation - Weighted Average Assumptions (Detail) - Stock Options	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	2.30%	2.90%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	4 years 4 months 17 days	5 years 5 months 5 days
Volatility	89.00%	82.00%

Share-Based Compensation - Stoc

Share-Based Compensation - Stock Option Activity (Detail) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Options
Options, Beginning Balance (in shares)	7,219,000
Options, Granted (in shares)	5,307,000
Options, Exercised (in shares)	0
Options, Forfeited (in shares)	(1,115,000)
Options, Cancelled and expired (in shares)	(457,000)
Options, Ending Balance (in shares)	10,954,000
Options, Vested or expected to vest (in shares)	10,510,000
Options, Exercisable (in shares)	4,047,000
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning balance (in USD per share)	$ 4.08
Weighted Average Exercise Price, Granted (in USD per share)	0.91
Weighted Average Exercise Price, Exercised (in USD per share)	0
Weighted Average Exercise Price, Forfeited (in USD per share)	2.16
Weighted Average Exercise Price, Cancelled and expired (in USD per share)	8.35
Weighted Average Exercise Price, Ending balance (in USD per share)	2.56
Weighted Average Exercise Price, Vested or expected to vest (in USD per share)	2.61
Weighted Average Exercise Price, Exercisable (in USD per share)	$ 4.39	$ 5.49
Weighted Average Remaining Contractual Term, Outstanding at end of period	8 years 3 months 18 days
Weighted Average Remaining Contractual Term, Vested and expected to vest at end of period	8 years 3 months 18 days
Weighted Average Remaining Contractual Term, Exercisable at end of period	7 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding at end of period	$ 3,504
Aggregate Intrinsic Value, Vested and expected to vest at end of period	3,252
Aggregate Intrinsic Value, Exercisable at end of period	$ 6

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Status of Nonvested Restricted Stock Awards (Detail) - Restricted stock units (RSUs) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Nonvested Shares
Nonvested Shares, Beginning balance (in shares)	13,000	63,000
Nonvested Shares, Issued (in shares)	0	0
Nonvested Shares, Vested (in shares)	0	(35,000)
Nonvested Shares, Forfeited (in shares)	(8,000)	(15,000)
Nonvested Shares, Ending balance (in shares)	5,000	13,000
Weighted Average Grant-Date Fair Value Per Share
Weighted Average Grant-Date Fair Value Per Share, Beginning balance (in USD per share)	$ 26.23	$ 15.93
Weighted Average Grant-Date Fair Value Per Share, Issued (in USD per share)	0	0
Weighted Average Grant-Date Fair Value Per Share, Vested (in USD per share)	0	12
Weighted Average Grant-Date Fair Value Per Share, Forfeited (in USD per share)	19.12	16.12
Weighted Average Grant-Date Fair Value Per Share, Ending balance (in USD per share)	$ 38.90	$ 26.23

Employee Benefit Plans (Detail)

Employee Benefit Plans (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Retirement Benefits [Abstract]
Maximum percentage of annual contributions per employee	80.00%
Discretionary matching contributions	$ 0.1	$ 0.2

Net Loss Per Share - Calculatio

Net Loss Per Share - Calculation of Basic & Diluted Net Loss (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Net loss attributable to common stockholders	$ (40,020)	$ (29,400)
Basic and diluted:
Weighted average shares outstanding (in shares)	57,980	56,106
Less: weighted average restricted shares outstanding (in shares)	(6)	(33)
Shares used in calculation of basic and diluted net loss per common share (in shares)	57,974	56,073
Net loss per common share: Basic and diluted (in USD per share)	$ (0.69)	$ (0.52)

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Anti-dilutive securities excluded from computation of let loss per share (in shares)	18.9	15.3

Related Party Transactions (Det

Related Party Transactions (Detail)	Mar. 12, 2020shares	Feb. 28, 2018shares	Mar. 31, 2017USD ($)	Dec. 31, 2018shares	Dec. 31, 2019
BVF Partners, L.P. | Series N Preferred Stock
Related Party Transaction [Line Items]
Number of shares converted (in shares)		575
BVF Partners, L.P. | Series O convertible preferred stock
Related Party Transaction [Line Items]
Conversion of stock (in shares)		12,575
Affiliated Entity | BVF Partners, L.P.
Related Party Transaction [Line Items]
percentage of common stock owned by others				12.00%	12.00%
Aequus Biopharma, Inc | Affiliated Entity | License And Promissory Note Termination, And Note Cancellation Agreements
Related Party Transaction [Line Items]
Amount funded to subsidiary | $			$ 347,500
Percent of milestone payments to be received			0.2
Milestone payments to be received | $			$ 20,000,000
Percentage of royalty payable to net sales			5.00%
Period from first commercial sale			10 years
License And Promissory Note | Convertible Debt | Aequus Biopharma, Inc | Affiliated Entity
Related Party Transaction [Line Items]
Debt cancelled and terminated | $			$ 13,700,000
Common Stock
Related Party Transaction [Line Items]
Stock Issued (in shares)		23,000,000		23,000,000
Conversion of stock (in shares)				(8,000,000)
Common Stock | BVF Partners, L.P.
Related Party Transaction [Line Items]
Stock Issued (in shares)		6,300,000
Number of shares converted (in shares)		8,000,000
Subsequent Event | Series X preferred Stock
Related Party Transaction [Line Items]
Number of shares converted (in shares)	0
Rights Offering | Subsequent Event | Series X preferred Stock
Related Party Transaction [Line Items]
Sale of stock (in shares)	4,429
Shares available for future conversion (in shares)	44,300,000
Rights Offering | Subsequent Event | BVF Partners, L.P. | Series X preferred Stock
Related Party Transaction [Line Items]
Number of shares converted (in shares)	0
Sale of stock (in shares)	3,047
Shares available for future conversion (in shares)	30,500,000

Commitments and Contingencies (

Commitments and Contingencies (Detail) - VAT Assessments € in Thousands, $ in Millions	1 Months Ended
	Mar. 31, 2014EUR (€)	Mar. 31, 2014USD ($)	Nov. 30, 2013EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2007EUR (€)	Dec. 31, 2006EUR (€)	Dec. 31, 2003EUR (€)
Loss Contingencies [Line Items]
Estimate of possible loss				€ 4,300	$ 4.8	€ 900	€ 2,800	€ 600
Taxes paid	€ 400	$ 0.6
Payments for attorney fees			€ 12

Income Taxes - Loss Before Inco

Income Taxes - Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
United States	$ (40,242)	$ (29,162)
Foreign	219	(190)
Net loss before noncontrolling interest	$ (40,023)	$ (29,352)

Income Taxes - Reconciliation B

Income Taxes - Reconciliation Between Effective and Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal income tax rate	21.00%	21.00%
Research and development tax credits	14.00%	6.00%
Non-deductible executive compensation	(2.00%)	(1.00%)
Valuation allowance	(31.00%)	(12.00%)
Expired tax attribute carryforwards	0.00%	(17.00%)
Gain on foreign entity liquidation	1.00%	3.00%
Foreign currency gains and losses	1.00%	2.00%
Unrecognized tax benefits	(3.00%)	0.00%
Other	(1.00%)	(2.00%)
Net effective tax rate	0.00%	0.00%

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 27,151	$ 18,792
Capitalized research and development	32,907	32,029
Research and development tax credit carryforwards	7,317	3,061
Stock-based compensation	3,109	2,940
Intangible assets	7,519	7,802
Depreciation and amortization	618	549
Lease liability	1,039
Other deferred tax assets	918	1,806
Total deferred tax assets	80,578	66,979
Less: valuation allowance	(79,506)	(66,698)
Deferred Tax Assets, Net of Valuation Allowance, Total	1,072	281
Deferred tax liabilities:
Right-of-use asset	(667)
Deductions for tax in excess of financial statements	(405)	(281)
Total deferred tax liabilities	(1,072)	(281)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax [Line Items]
Net operating losses with an indefinite life	$ 48,700,000
U.S. federal tax credits	7,300,000	$ 3,100,000
Net operating loss deferred tax assets	27,151,000	18,792,000
Increase (decrease) in valuation allowance	12,800,000
Unrecognized tax benefits	1,268,000	0	$ 0
Accrued interest or penalties related to unrecognized tax benefits	0
United Kingdom
Income Tax [Line Items]
Net operating loss carryforwards	40,900,000
Aequus Biopharma, Inc
Income Tax [Line Items]
Net operating loss deferred tax assets	$ 10,300,000
Interest in majority-owned subsidiary	59.70%
Domestic Tax Authority
Income Tax [Line Items]
Net operating loss carryforwards	$ 92,000,000	56,600,000
State and Local Jurisdiction
Income Tax [Line Items]
Net operating loss carryforwards	$ 12,700,000	$ 18,000,000

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of period	$ 0	$ 0
Gross increases to tax positions in prior periods	633	0
Gross increases to tax positions in current periods	635	0
Balance at end of period	$ 1,268	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 12, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 24, 2018	Jan. 23, 2018
Subsequent Event [Line Items]
Offering costs		$ 275	$ 268
Preferred stock par value (in USD per share)				$ 0.001	$ 0
Series X preferred Stock | Subsequent Event
Subsequent Event [Line Items]
Number of shares converted (in shares)	0
Preferred stock par value (in USD per share)	$ 10,000
Shares issued upon conversion of share (in shares)	10,000
Maximum ownership upon conversion	9.99%
Rights Offering | Subsequent Event
Subsequent Event [Line Items]
Proceeds from common stock offering	$ 60,000
Offering costs	$ 700
Rights Offering | Common Stock | Subsequent Event
Subsequent Event [Line Items]
Sale of stock (in shares)	15,700,000
Rights Offering | Series X preferred Stock | Subsequent Event
Subsequent Event [Line Items]
Sale of stock (in shares)	4,429
Shares available for future conversion (in shares)	44,300,000

Uncategorized Items - ctic-2019

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,196,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	1,203,000
Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (7,000)